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HIV pre-exposure prophylaxis is the use of antiretroviral drugs, including dapivirine and 
tenofovir, in uninfected individuals to prevent the establishment of infection. Dapivirine 
is being developed as a topical microbicide for application to the vaginal and colorectal 
mucosa, and tenofovir is in clinical use as an oral formulation with a topical gel 
formulation for the vaginal and colorectal mucosa undergoing further clinical trials. The 
metabolism of dapivirine is unknown, and understanding the metabolism of tenofovir is 
particularly important because it is a prodrug that must be phosphorylated intracellularly 
to yield the active metabolite, tenofovir diphosphate. Dapivirine and tenofovir 
diphosphate must be present in the colorectal and vaginal mucosa for HIV prevention; 
tenofovir diphosphate must also be produced in white blood cells for oral HIV treatment 
and prevention and in hepatocytes for hepatitis B treatment. A comprehensive 
understanding of the metabolism that impacts drug exposure in these tissues is imperative 
for optimal drug use. 
 The metabolism of dapivirine is not yet known, nor has a full understanding of 
drug metabolism in the mucosal tissues been defined. The enzymes proposed to be 
involved in dapivirine metabolism are the cytochromes P450 (CYPs) and UDP-
glucuronosyltransferases (UGTs). Immunoblotting revealed that CYP2B6, -2C19, -3A4, 
and -3A5were more highly expressed in vaginal tissues as compared to colorectal tissues. 
A liquid chromatography mass spectrometry assay was developed to identify and 
characterize 11 novel metabolites of dapivirine which were produced by the CYPs, 
UGTs, or both. In vitro metabolism assays were used to identify members of the CYP3A 
family as the primary enzymes responsible for dapivirine metabolism. The dapivirine 
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mass spectrometry assay was then used, leveraging dapivirine as a small molecule probe, 
to demonstrate CYP activity in both colorectal and vaginal tissues, but UGT activity only 
in colorectal.  
 While creatine kinase, adenylate kinase, and pyruvate kinase have been 
implicated in tenofovir’s activation, these studies were carried out in vitro and do not 
investigate whether these enzymes are expressed in the tissues of clinical relevance. 
Immunoblots revealed that the four creatine kinases and adenylate kinase 2 are more 
highly expressed in colorectal tissue compared to vaginal tissue and white blood cells, 
whereas the two pyruvate kinases displayed the opposite trend. Additionally, adenylate 
kinase 2, creatine kinase muscle, and both pyruvate kinases were expressed in primary 
human hepatocytes. An ion pairing liquid chromatography mass spectrometry assay was 
utilized to directly detect tenofovir phosphorylation. This assay was used to in 
combination with siRNA mediated knockdowns to show that AK2, PKM, and PKLR are 
responsible for activating tenofovir in white blood cells and vaginal tissues, whereas AK2 
and CKM perform the same function in colorectal tissues. 
 Collectively, these findings represent a fundamental shift in the current 
understanding of drug metabolism in the body. Not only are colorectal tissues and vaginal 
tissues able to biotransform drugs, but they do it in a tissue specific manner. I anticipate 
that these results lay the groundwork for future studies in tissue specific drug metabolism 
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Chapter 1: Introduction 
HIV Pre-exposure Prophylaxis 
There are multiple routes for transmission of HIV-1, but the most prevalent is through 
vaginal or anal intercourse [1]. Through efforts including male circumcision and 
increased condom use, the amount of new human immunodeficiency virus (HIV) 
infections decreased from 3.4 million in 2001 to 2.3 million in 2013 [2]. The use of 
antiretroviral therapy in conjunction is predicted to further accelerate the decline of 
infection rates. It is already known that antiretroviral therapy in the infected individual 
reduces viral load and therefore chance of HIV-1 transmission [2]. Pre-exposure 
prophylaxis (PrEP) is a promising new prevention strategy that uses antiretrovirals to 
interrupt the viral life cycle before infection is established in newly exposed individuals 
[3]. Evidence supporting the potential efficacy of PrEP comes from postnatal 
transmission prophylaxis and macaque model studies [4, 5].  
 In July 2012, Truvada® became the first antiretroviral drug to be approved for use 
in HIV PrEP by the United States Food and Drug Administration [6]. Truvada® is a once 
daily oral coformulation of emtricitabine and a prodrug of tenofovir. Tenofovir and 
emtricitabine are also coformulated with the non-nucleoside reverse transcriptase 
inhibitor efavirenz into Atripla®, a highly effective once daily pill that is now prescribed 
to 80% of treatment naïve HIV patients in the United States [7]. Tenofovir and 
emtricitabine are nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs) 
that require intracellular phosphorylation to yield their active metabolites: tenofovir 
diphosphate and emtricitabine triphosphate [8]. Advantages include the lack of 
mitochondrial toxicity that is typical of NRTI drugs, drug action early in the viral life 
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cycle, and long intracellular half lives of their active metabolites [9]. Tenofovir and 
emtricitabine are strongly synergistic, most likely because tenofovir is a purine analog 
while emtricitabine is a pyrimidine analog [10]. When given orally, tenofovir’s poor oral 
bioavailability necessitates use of the prodrug tenofovir disoproxil fumarate [9]. Despite 
these advantages, however, the clinical trials examining tenofovir use for HIV PrEP have 
not been unequivocally successful.  
Out of six completed PrEP clinical trials testing oral tenofovir alone or in 
conjunction with emtricitabine, four demonstrated a significant reduction in HIV 
transmission. Of the successful trials, iPrEx, TDF2, and Partners PrEP used once daily 
oral tenofovir/emtricitabine to demonstrate 44%, 62%, and 75% reduction in HIV 
infectivity, respectively [11-13]. Partners PrEP also and the Bangkok Tenofovir study 
tested oral tenofovir alone, and found it to yield 67% and 48.9% reduction in infectivity, 
respectively, nearly as effective as the tenofovir/emtricitabine combination [13, 14]. The 
unsuccessful trials were FEM-PrEP, using once daily oral tenofovir/emtricitabine dosing 
and two subsets of VOICE using once daily oral tenofovir or tenofovir/emtricitabine [15, 
16]. Analysis of drug levels in plasma indicate that adherence was relatively low in the 
FEM-PrEP, VOICE, and iPrEx trials, but iPrEx showed 44% reduction in HIV infectivity 
among homosexual men whereas FEM-PrEP and VOICE could not demonstrate similar 
protection for heterosexual women [11, 15, 17]. This may be due to the fact that orally 
dosed tenofovir results in drug levels that are 100 fold higher in rectal than in vaginal 
tissue [18, 19], leading to greater forgiveness of nonadherence in iPrEx. Pharmacologic 
reasons for this differential distribution remain to be determined. 
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Many of the trials demonstrated a strong correlation between detectable drug 
levels in blood plasma and increased protection from HIV infection. However, in patients 
infected despite PrEP, systemic drug levels could select for drug resistant mutations. 
Topically applied microbicides have the potential to overcome this disadvantage of oral 
dosage since the systemic concentrations achieved are lower and put less selective 
pressure on resistant virus mutants. In addition, topical dosing yields higher 
concentrations of antiretroviral drugs in mucosal tissues [20]. This has recently been 
demonstrated for both vaginally and rectally applied tenofovir microbicides [21, 22]. 
Formulations using tenofovir or dapivirine have progressed farthest in microbicide 
development, with a completed phase III trial for tenofovir (CAPRISA 004) and an 
ongoing phase III trials for dapivirine [23]. In the CAPRISA 004 trial, 1% tenofovir gel 
was applied to the vagina 12 hours pre and post intercourse, resulting in 39% protection 
overall and up to 54% protection from HIV infection in the high adherence participants 
[24]. Additionally, the CAPRISA trial demonstrated no selection for viral strains with 
enhanced fitness, no impact on the number of viruses transmitted in seroconverted 
individuals, and protection from herpes simplex virus infection [25, 26]. The 
unanticipated protection from herpes simplex virus is likely due to the higher tenofovir 
levels in cerviovaginal tissue that result from topical dosing [27]. In contrast, the daily 
1% tenofovir gel subset of VOICE was stopped early because there was no discernable 
protection, likely due to poor adherence [16]. Current phase III clinical trials following 
up on the success of CAPRISA 004 include CAPRISA 008, which aims to develop a 
model for tenofovir gel distribution through family planning and analyze gel safety, and 
FACTS 001, a larger scale repetition of CAPRISA 004 [28, 29]. 
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As stated above, dapivirine is another antiretroviral drug that has made significant 
progress in HIV PrEP trials. Dapivirine is one of the diarylpyrimidine non-nucleoside 
reverse transcriptase inhibitors (NNRTI), which inhibit HIV reverse transcriptase through 
allosteric binding. First generation NNRTIs were known for their low genetic barriers to 
resistance [30, 31]. Diarylpyrimidine NNRTIs such as dapivirine are conformationally 
flexible, resulting in higher genetic barriers without compromising anti-HIV activity [32]. 
While the oral bioavailability of dapivirine is an ongoing debate [23], many conclude that 
dapivirine does not have good oral bioavailability [20], leading to its development as 
primarily a topical microbicide. Current trials using dapivirine include ASPIRE (MTN 
020) and  The Ring Study (IPM 027), both of which aim to test the safety and efficacy of 
a monthly dapivirine vaginal ring [33, 34]. Multiple phase I and II trials using dapivirine 
formulated in gels and a phase I trial of a vaginal ring (MTN 013/IPM 026) testing a 
coformulation of dapivirine with the entry inhibitor maraviroc have been completed [35]. 
MTN 013 showed that dapivirine penetrated the cervicovaginal tissues and was able to 
prevent HIV infection of vaginal biopsies obtained from study participants [36]. 
Maraviroc, on the other hand, had poor vaginal tissue penetration, which is an interesting 
contrast with a previous study showing effective vaginal tissue penetration from oral 
maraviroc administration [37]. 
Drug Metabolism 
 The majority of drugs are taken orally, due to the ease of administration thus 
leading to high patient compliance. Orally administered drugs must bypass several 
barriers before reaching the systemic circulation for delivery to their targeted tissues. 
Upon ingestion, a drug will proceed to the intestines where it can be absorbed into the 
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bloodstream through intestinal villi. While lipophilic compounds may readily diffuse 
across the intestinal epithelium, others may require the assistance of transport enzymes 
[38]. The uptake of drugs is referred to as phase 0 transport or absorption [39]. Some 
chemical modification, known as metabolism, may occur during this stage. Blood from 
the intestinal villi is carried through the hepatic portal vein to the liver, which is the 
primary organ for drug metabolism and detoxification. Enzymes within the liver’s 
hepatocytes metabolize compounds present in the blood; this stage is known as phase I 
and phase II metabolism. Metabolites formed in the liver and their parent drugs may 
proceed to the heart through the hepatic vein or be returned to the gastrointestinal system 
via the enterohepatic circulation, where they will join intestinally formed metabolites and 
unabsorbed drug to be excreted via the rectum. Once within the heart chambers, drugs 
and metabolites are a part of the systemic circulation and can proceed to their targeted 
tissues to exert their biological effect or be excreted through the renal system. This final 
excretion step is known as phase III transport [39]. The overall consequence of drug 
metabolism is to increase the polarity of compounds to facilitate their excretion. Figure 1 
provides a summary of these processes [40]. However, the metabolites of a drug may 
retain pharmacologic activity, lose pharmacologic activity, or gain novel pharmacologic 
activity or toxicity. Drug absorption, distribution, metabolism, and excretion together 
determine the disposition of a drug and its metabolites, which often obstructs the progress 
of or eliminates drugs under clinical development [41, 42]. 
 Phase I metabolism is primarily mediated by the cytochromes P450 (P450s), 
which are discussed in far greater detail below. In general, phase I metabolism serves to 
introduce functional groups into drugs, which can be further modified. The metabolite  
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Figure 1. (Borrowed from [40]) The fate of an orally administered drug in the human 
body. Drugs must are absorbed across the intestinal membrane and arrive in the liver. 
The liver carries out the bulk of drug metabolism, and metabolites may return to the 
intestine or proceed with the parent drug into the systemic circulation. From the systemic 
circulation, parent drug and its metabolites may proceed to tissues and sites of action 
where they can exert biological effects, or be excreted through the renal or pulmonary 
system. Excretion also occurs rectally from the intestine; this will primarily be excretion 








tends to be more hydrophilic than the parent drug; an example is the reaction of a –CH3 
to –CH2OH. In addition to oxygenations, other P450-mediated oxidation reactions that 
contribute to phase I metabolism are heteroatom release, epoxidation, and group 
migration [43]. Phase II metabolism consists of conjugation reactions that add additional 
hydrophilic moieties to functional groups on molecules. While these functional groups 
are typically introduced into the drug during phase I metabolism, phase I metabolism is 
not required for phase II metabolism to occur; often the functional groups are present in 
the parent drug [44]. Enzymes responsible for phase II metabolism include the uridine 5’-
diphospho-glucuronosyltransferases (UGTs) and sulfotransferases (SULTs). Nucleophilic 
functional groups on drug molecules are modified by UGTs to add glucuronic acid and 
by SULTs to add sulfonate [45, 46].  Although glucuronidation and sulfonylation are 
generally considered detoxifying, there are exceptions. The most notable example is the 
glucuronidation of morphine to produce its 6β-glucuronide, which has 90-650 fold 
greater potency than morphine itself [47]. 
 Drug metabolism varies widely across individuals, populations, and throughout an 
individual’s life. In the generalized case where drug metabolism deactivates a drug and 
decreases systemic drug concentrations, individuals who are extensive metabolizers may 
require higher than normal doses to reach drug therapeutic windows, whereas those who 
are poor metabolizers may accumulate drug over time and experience negative side 
effects [42]. If metabolism of a particular drug serves to activate it, as in the case of 
prodrugs, or generate toxic metabolites, extensive metabolizers would need to be given 
lower doses and poor metabolizers would require higher doses to reach therapeutic 
windows while avoiding toxicity. Genetic variation and differential expression of drug 
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metabolizing enzymes account for much of the variability between individuals. For 
example, individuals with mutant alleles of CYP2C9, one of the P450 isozymes, display 
up to 60% reduced clearance of the antithrombotic warfarin [48]. In order to ensure 
coagulant action and minimize risk of bleeding,  patients must be genotyped and the 
warfarin dosage decreased if one of the variant alleles is detected [49]. Drug dosing also 
cannot safely be assumed to be similar between pediatric and adult patients. In addition to 
the differences in size, pediatric and adult patients have differences in both phase I and II 
metabolizing enzymes. Many of the P450 isozymes are undetectable in the fetal liver and 
only reach adult expression levels later in maturation [50]. UGTs are similarly deficient 
in infancy whereas SULTs are essentially mature at birth, allowing SULTs to compensate 
for the lack in UGT activity [50].  
 An individual’s drug metabolizing ability may change based on environmental 
and health factors as well. Grapefruit juice is known for elevating the systemic 
concentrations of drugs when taken concomitantly, increasing toxicity risk. This is due to 
the presence of bergamottin, a strong inhibitor of many P450 isozymes, in particular 
CYP3A4 [51]. As such, patients receiving drugs that are known to be metabolized by 
CYP3A4 are told to avoid grapefruit juice [52]. Patients on a long term drug regime who 
experience onset of inflammation are also at higher risk for drug toxicities, as seen when 
an influenza outbreak caused theophylline toxicity in many asthmatic children [53]. The 
inflammatory state is known for transcriptional inhibition of P450s in multiple tissues. It 
is generally accepted that this alteration is due to the increase in pro-inflammatory 
cytokines. Notably, however, inflammation resulting from different infectious pathogens 
result in differential alterations in P450 expression [54]. A thorough understanding of an 
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individual’s drug metabolism ability and how it may change is crucial for the 
optimization of drug dosing. 
Cytochromes P450 
 In 1958, Garfinkel and Klingenberg both published studies reporting the detection 
of a strong absorption at 450 nm when carbon monoxide reacted with reduced pig and rat 
liver microsomes [55, 56]. This characteristic resulted in the naming of the cytochromes 
P450, which we now know to be a superfamily of heme-containing [57] proteins 
responsible for the oxidation of both endogenous and exogenous substrates [58]. P450s 
are found in most organisms, with 102 genes known in mice and 57 known in humans 
[59]. Protein expression is primarily in the endoplasmic reticulum of the liver, though 
there is also significant evidence of P450 expression in the pancreas, skin, brain, and 
gastrointestinal tract [60]. P450s are of particular interest in drug metabolism because a 
small subset of approximately 12 human P450s are responsible for the biotransformation 
of 70-80% of all clinically used drugs [61]. 
 The canonical reaction catalyzed by P450s is the nicotinamide adenine 
dinucleotide phosphate (NADPH) dependent oxidation of an organic substrate by the 
introduction of an oxygen: NADPH + H+ + O2 + RHNADP+ + H2O + ROH [43]. 
Figure 2 depicts the generalized P450 catalytic cycle. Following substrate binding, 
NADPH-cytochrome P450 oxidoreductase donates an electron, reducing the ferric heme 
to a ferrous state. Oxygen then binds to the ferrous heme followed by a second electron 
that can be donated by NADPH-cytochrome P450 oxidoreductase or cytochrome b5. 
With the addition of a proton and the cleaving of the oxygen-oxygen bond, H2O is 




Figure 2. (Borrowed from [62] ) Cytochrome P450 catalytic cycle. Following the 










create a radical, which then reacts with FeOH3+ to create ROH. This generalized catalytic 
cycle results in a variety of possible modifications to organic substrates, including carbon 
oxygenation, heteroatom oxygenation, heteroatom dealkylation, and epoxidation. P450 
catalyzed reactions increase hydrophilicity of molecules and add functional groups for 
additional modification that further facilitates compound excretion. In some cases, the 
metabolites may retain, gain, or lose the pharmacological activity of the parent 
compound. Metabolites may also be toxic, thus causing the side effects experienced when 
using many drugs [42].  
 Human P450s are membrane bound 57 kDa proteins (~ 500 amino acids) 
containing a single heme group, which is anchored via the thiolate ligand of a conserved 
cysteine residue [63]. General enzyme structure is characterized by twelve highly 
conserved α-helices designated A through L and an N-terminal β-sheet region [64]. 
Helices C, D, and I-L comprise the heme and protein partner binding sites whereas F-G, 
B-C, and the N- and C-terminal regions form the substrate binding sites. The F-G helix in 
particular is known to slide over the I helix, opening and closing the active site channel 
[65]. P450s are primarily found in the endoplasmic reticulum, anchored by an N-terminal 
transmembrane peptide [66].  The NADPH-cytochrome P450 oxidoreductases that 
provide the requisite electrons are also located in the endoplasmic reticulum [67]. 
 P450s have an established nomenclature that relies on amino acid sequence 
similarity. Individual genes are referred to by “CYP,” followed by a number designating 
its family, a letter designating its subfamily, and a number representing the gene. 
Members within the same family have greater than 40% sequence identity and members 
within the same subfamily have greater than 55% sequence identity [68]. The enzymes 
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commonly associated with drug metabolism are CYP1A2, -2A6, -2B6, -2C8, -2C9, -
2C19, -2D6, -2E1, -3A4, and -3A5.  
 Of the drug metabolizing P450s, CYP3A4 is the most abundantly expressed in the 
liver, comprising 14.5-37% of the total hepatic P450 content. The CYP3A family is 
known for metabolizing the largest proportion, 30%, of clinically used drugs [61]. Many 
substrates of CYP3A4 are also substrates of CYP3A5, perhaps due to the 84% amino 
acid similarity between the two proteins [69]. Extrapolation of an individual’s relative 
CYP3A4 and -3A5 activity is possible due to varying levels of activity on the same 
substrate. For example, when the psychoactive drug midazolam is metabolized, CYP3A5 
produces a greater ratio of the 1-hydroxy metabolite to the 4-hydroxy metabolite than 
does CYP3A4 [70]. An additional reaction catalyzed by CYP3A4/5 is the metabolism of 
testosterone to its 6β hydroxylated metabolite. Due to the selective production of these 
midazolam and testosterone metabolites by CYP3A4/5, they are known as prototypic 
substrates and monitoring of these reactions is commonly used to quantify CYP3A4/5 
activity. The antifungal ketoconazole is a known mixed competitive-noncompetitive 
inhibitor of CYP3A enzymes; thus it can also be leveraged to study enzyme activity [71]. 
 The CYP2C family is responsible for the metabolism of approximately 20% of 
clinically used drugs and comprise 20% of the total hepatic P450 proteins [72]. There are 
four members of the family in humans, CYP2C8, -2C9, -2C18, and -2C19. While 
CYP2C18 mRNA has been detected in multiple tissues, there is no known evidence of 
expression on the protein level [73]. In the liver CYP2C9 protein is found in the greatest 
amounts, followed by CYP2C8 then CYP2C19 [72]. Despite the high DNA and protein 
sequence similarity (82%) between the individual enzymes, the enzymes metabolize 
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markedly different substrates. Prototypic substrate reactions include the following: 6α-
hydroxylation of cancer chemotherapeutic paclitaxel for CYP2C8, 4’-hydroxylation of 
the nonsteroidal anti-inflammatory drug diclofenac for CYP2C9, and 4’-hydroxylation of 
the anticonvulsant mephenytoin for CYP2C19 [61]. Inhibitors used to study CYP2C 
activity include the antibacterial sulfaphenazole, which competitively inhibits CYP2C9 
and (+)-N-3-benzyl-nirvanol, which inhibits CYP2C19 [74, 75]. 
 The remaining members of the CYP2 family that are involved in drug metabolism 
are CYP2A6, -2B6, -2D6, and -2E1. They make up 3.5-14%, 1.7-5.3%, 1.3-4.3%, and 
5.5-16.5% of the total hepatic P450 protein, and metabolize 3.4%, 7.2%, 20%, and 3% of 
clinically used drugs, respectively [61]. CYP2A6 is well known for participating in the 
metabolism of nicotine and various other carcinogens, though its prototypic substrate 
reaction is the 7-hydroxylation of coumarin [76]. CYP2B6 catalyzes the 4-hydroxylation 
of the antidepressant buproprion and the 8-hydroxylation of the anti-HIV drug efavirenz 
[77, 78], and is inactivated in a mechanism dependent fashion by 2-phenyl-2-(1-
piperidinyl)propane, an analog of the recreational drug phencyclidine [79]. CYP2D6 is 
required for the bioactivation of codeine into morphine by O-demethylation, causing 
adverse effects for patients with high CYP2D6 activity [80].  The antiarrhythmic agent 
quinidine is a potent competitive inhibitor of CYP2D6 activity [81]. CYP2E1 is ethanol 
inducible and N-hydroxylates acetaminophen to its toxic metabolite N-acetyl-p-
benzoquinoneimine, making CYP2E1 is the enzyme responsible for alcohol induced 
acetaminophen hepatotoxicity [82]. 
 Lastly, CYP1A2 comprises 4.4-16.3% of the hepatic P450 proteins and is 
responsible for metabolizing 8.9% of clinically used drugs [61]. It is best known for 
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being the sole enzyme responsible for catalyzing the 1-N and 3-N-demethylation of 
caffeine [83]. CYP1A2 also catalyzes the O-deethylation of the once widely used 
analgesic phenacetin to produce acetaminophen. Phenacetin was discontinued due to its 
association with renal and urinary tract carcinogenicity, however it has been shown that 
CYP1A2 carries out a primarily detoxifying role and that other P450s are responsible for 
production of toxic metabolites from phenacetin [84]. Furafylline, a compound that was 
synthesized in hopes of replacing the asthmatic drug theophylline, is a selective 
mechanism based inhibitor of CYP1A2 [85]. 
 Because this small subset of enzymes is responsible for metabolizing the majority 
of clinically used drugs, P450s mediate many observed drug-drug interactions. Often, one 
drug will induce or inhibit the expression or activity of a P450 that plays a role in the 
metabolism of another drug [86]. A frequently cited example is the interaction between 
alcohol and acetaminophen, which was already described above due to its dependence on 
CYP2E1 induction and activity. Additionally, the anti-tuberculosis drug rifampicin has 
been shown to reduce systemic concentrations of the cancer drug erlotinib when 
administrated together [87]. Rifampicin is known to induce the expression of CYP3A4 
through activation of the pregnane-X-receptor (PXR), which is a key transcriptional 
regulator of many drug metabolizing enzymes including CYP2A6, -2B6, -2C, and -3A 
members [88]. In order to predict drug-drug interactions, a sufficient understanding of the 
transcriptional regulation of CYPs is necessary. Other transcriptional regulators of P450 
expression include the aryl hydrocarbon receptor (AhR) which regulates CYP1A, the 
constitutive androstane receptor (CAR) which regulates CYP2A, -2B6, -2C, and -3A, the 
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hepatocyte nuclear factor 1 alpha (HNF1α) which regulates CYP2E1, and hepatocyte 
nuclear factor 4 alpha (HNF4α) which regulates CYP2C and -2D6 [61].  
 While the liver is the major site of oral xenobiotic metabolism, drugs that are 
administered topically, such as the HIV PrEP microbicides, are unlikely to encounter 
hepatic tissue. Thus, local tissue metabolism will be the primary mediator of 
pharmacokinetics of topically applied drugs. The tissues of relevance when studying HIV 
PrEP are the colorectal and vaginal mucosa. Expression of CYP1A2, -2C, -2E1, -3A4, 
and -3A5 has been found on the mRNA level [89-91] and expression of CYP2C8, -2E1, -
3A4, and -3A5 have been found on the protein level in colorectal tissues [90]. Expression 
of CYP1A1, -2C8, and -3A4 mRNA [92, 93] and expression of CYP1A, -2B, -2C, and -
3A protein have been found in the cervicovaginal tissues [94]. However, P450 activity 
has not been clearly demonstrated in either mucosal tissue, nor have potential differences 
between hepatic and mucosal metabolism been examined. 
Nucleotide Kinases 
Tenofovir is a NRTI that requires two intracellular phosphorylation steps to yield its 
active metabolite, tenofovir-diphosphate. This is advantageous compared to nucleoside 
analog reverse transcriptase inhibitors, which require three phosphorylation steps with the 
first step often being rate limiting [95]. Tenofovir diphosphate mimics the nucleotide 
triphosphates that are the natural substrates of HIV reverse transcriptase and is 
incorporated into the growing viral DNA chain. However, due to the lack of a 3’-OH on 
tenofovir and its metabolites, reverse transcriptase cannot extend the chain beyond 
tenofovir and DNA synthesis halts [96]. In order to ensure the efficacy of tenofovir, 
expression and activity of the enzymes that catalyze the phosphorylation steps must be 
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understood in the cells of importance: CD4+ T cells, systemically and within the 
colorectal and vaginal mucosa (HIV), and hepatocytes (Hepatitis B virus). Many studies 
which have identified enzymes capable of participating in tenofovir activation were 
performed in vitro with purified enzymes or subcellular fractions. 
 Adenylate kinases (AKs) are participants in the de novo and salvage pathways of 
nucleotide synthesis, and are known for catalyzing the reversible transfer of a phosphate 
group from adenosine triphosphate (ATP) to adenosine monophosphate, resulting in two 
molecules of adenosine diphosphate [97]. Nine individual adenylate kinases have been 
identified and they have been shown to have differential subcellular localizations and 
tissue distributions [97, 98]. AK1, AK7, and AK8 are solely found in the cytosol, AK2, 
AK3, and AK4 are found in the mitochondria, and AK5 and AK9 can be found in either 
the cytosol or nucleus. Only AK1 and AK6 are known to be expressed in all tissues, 
whereas AK5 is expressed only in brain and the others are found in various subsets [97]. 
The individual isoforms also display different donor specificities. The fact that AK2 is 
able to use all nucleotide triphosphates and AK3 only uses guanine triphosphate and 
inosine triphosphate was leveraged to show that adefovir, an analog of tenofovir, is 
phosphorylated by AK2 and not AK3 in an in vitro system using mitochondrial and 
cytosolic cell extracts [99]. The susceptibility of AK1 to inactivation by sulfhydryl 
reagents also eliminated AK1 as a candidate for adefovir phosphorylation. Additionally, 
AK2 isolated from both human and mouse lymphoid cell lines was shown to 
phosphorylate tenofovir [99, 100]. The remaining adenylate kinases have not been 
examined for their activity towards tenofovir or other adenine analogs. 
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 There are two groups of guanylate kinases (GUKs), the nucleotide 
phosphorylating and membrane associated [98]. The membrane associated GUKs have 
function primarily as scaffold proteins in tissue development and differentiation [101]. 
Due to their lack of phosphoryl transfer activity, membrane associated GUKs are not 
implicated in the activation of nucleoside analog drugs. However, the nucleotide 
phosphorylating guanylate kinases (NPGUKs) catalyze the phosphorylation of guanosine 
monophosphate to guanosine diphosphate using ATP as a phosphate donor [102]. Similar 
to AKs, NPGUKs also participate in both the de novo and salvage pathways of nucleotide 
synthesis. There have been three isozymes of NPGUKs identified [103, 104], though only 
GUK1 has been cloned and therefore it is the most well studied [98]. GUK1 has been 
shown to phosphorylate guanosine analog antivirals such as acyclovir, ganciclovir, and 
cyclopropavir [105]. Adenine and guanine are highly similar nucleobases, so it is 
conceivable that GUK1 may also be able to phosphorylate adenine analogs, but this has 
ever been examined. 
 Nucleotide diphosphate kinases (NDPKs) catalyze the phosphorylation of 
nucleotide diphosphates to nucleotide triphosphates without being selective for purines or 
pyrimidines [97]. They play key roles in both the de novo and salvage pathways of 
nucleotide synthesis, participate in cell differentiation and development, regulate gene 
expression, and are implicated in tumor metastasis [106, 107]. NDPKs are commonly 
implicated in catalyzing the last phosphorylation step for all NRTIs [9, 108] and have 
been shown to activate the antivirals azidothymidine, dideoxyadenosine, and ribavirin 
[109, 110]. However, studies examining the NDPK activity towards tenofovir disagree, 
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with one study showing low efficiency production of tenofovir diphosphate [111] and the 
other lacking any detectable activity [112].   
 Creatine kinases (CKs) catalyze the reversible phosphorylation of creatine to 
phosphocreatine, using ATP as a phosphate donor. Phosphocreatine is an alternate source 
of cellular energy that can be used to create ATP when necessary [113]. The two 
cytosolic isoforms of creatine kinase are the brain type (CKB) and muscle type (CKM). 
They are expressed as homodimers or heterodimers, with CKMM being found in muscle 
and heart, CKMB found heart, and CKBB found in brain, kidney, retina, and various 
other tissues [114, 115]. The two mitochondrial CK isoforms are localized to the outer 
mitochondrial compartment and are known as the ubiquitously expressed isoform 
(CKMT1) and the sarcomeric isoform (CKMT2). They are expressed as homodimers and 
homooctamers, with CKMT1 expressed in a wide variety of cells and tissues and 
CKMT2 primarily expressed in muscle tissue [114]. Serum mitochondrial CK levels are 
known to increase in response to tenofovir administration, which is possibly linked to the 
renal tubulopathy that is sometimes associated with tenofovir [116]. Although creatine is 
not structurally similar to nucleotides, the reverse reaction used to generate ATP can be 
leveraged to phosphorylate adenine analog drugs. Human CKBB, CKMM, and CKMB 
have been shown to efficiently phosphorylate tenofovir monophosphate to yield tenofovir 
diphosphate in in vitro systems [111, 112].  
 Pyruvate kinases (PKs) are key rate-limiting enzymes in the glycolytic pathway 
that can only act in one direction [117]. They catalyze the transfer of a phosphate group 
from phosphoenolpyruvate to ADP, thus producing pyruvate and ATP [118]. There are 
two PK genes which translate into four isozymes. The muscle PK gene (PKM) can be 
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differentially spliced to yield PKM1, expressed in skeletal muscle, heart, and brain, and 
PKM2, expressed in early fetal tissues and most adult tissues. The liver and red blood cell 
gene (PKLR) encodes both PKR, which is expressed in red blood cells, and PKL, which 
is primarily found in the liver [119].  Many diseases are associated with PKs; examples 
include PMK2’s role in promoting the Warburg effect in cancer [120] and PKR 
deficiency leading to anemia [121]. Rabbit PKM has been shown to phosphorylate 
tenofovir monophosphate in vitro, but studies have not been carried out with human 
enzymes [111, 112]. 
Summary 
It is evident that metabolism by the P450s has potential to result in adverse events which 
cannot be predicted without understanding how P450s act on every drug that is 
administered. Dapivirine is one drug whose metabolism is yet unknown. However, 
because all other NNRTIs have shown themselves to be metabolized by P450s, it is likely 
that P450s also act on dapivirine. Because dapivirine is only being given topically to the 
colorectal or vaginal mucosa, P450 expression and activity in these tissues must also be 
investigated. An understanding of local drug metabolism will help to inform the use of 
many drugs in the colorectal and vaginal tissues, including contraceptives, spermicides, 
and the HIV drug maraviroc which is also being developed for microbicide use. 
 While multiple kinases have been shown to phosphorylate tenofovir in in vitro 
assays, these studies do not account for the presence of other potentially competing 
nucleotide kinases or the differences in enzyme expression and activity within the cells of 
clinical relevance. Thus the pathway for tenofovir activation is not yet understood in 
white blood cells, vaginal tissues, colorectal tissues, and liver tissues. The possibility of 
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tissue specific activation differences may be an intriguing explanation for the clinical 
observation that tenofovir-diphosphate is found in greater quantities in colorectal versus 
vaginal tissues. Such an understanding would allow pharmacogenetic investigation to 
explore potential inter-individual differences in NRTI activation and inform the use of 
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Chapter 2: Dissimilarities in the metabolism of antiretroviral drugs used in HIV 
pre-exposure prophylaxis in colon and vagina tissues 
 
Abstract: 
Attempts to prevent HIV infection through pre-exposure prophylaxis (PrEP) include 
topical application of anti-HIV drugs to the mucosal sites of infection; however, a 
potential role for local drug metabolizing enzymes in modulating the exposure of the 
mucosal tissues to these drugs has yet to be explored. Here we present the first report that 
enzymes belonging to the cytochrome P450 (P450) and UDP-glucuronosyltransferase 
(UGT) families of drug metabolizing enzymes are expressed and active in vaginal and 
colorectal tissue using biopsies collected from healthy volunteers. In doing so, we 
discovered that dapivirine and maraviroc, a non-nucleoside reverse transcriptase inhibitor 
and an entry inhibitor currently in development as microbicides for HIV PrEP, are 
differentially metabolized in colorectal tissue and vaginal tissue. Taken together, these 






Pre-exposure prophylaxis (PrEP) is a promising new strategy to prevent the spread of 
human immunodeficiency virus (HIV) by using antiretroviral (ARV) therapy to interrupt 
the viral life cycle before infection is established in newly exposed individuals [1]; 
however, oral ARV drugs may select for drug resistant viral strains in patients who 
become infected while on the prophylactic regimen. Topically applied microbicides may 
overcome this disadvantage by preventing the establishment of infection within the 
mucosal tissues without resulting in significant systemic exposure [2]. A 
pharmacokinetics study of tenofovir, which is one of the two drugs that comprise the 
therapy Truvada®, currently the only antiretroviral therapy FDA approved for HIV PrEP, 
corroborates this by demonstrating lower systemic and higher mucosal concentrations of 
tenofovir and its active metabolite when dosed vaginally versus orally [3].  
Dapivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) currently 
undergoing phase III clinical trials for use in HIV PrEP [4]; however, due to its poor oral 
bioavailability and remarkable inhibitory activity against both cell-associated and cell-
free virions [2], dapivirine is in development solely as a topical microbicide. Maraviroc is 
an entry inhibitor co-formulated into a vaginal ring with dapivirine that is currently 
undergoing phase I clinical trials [5]. The factors that might modulate dapivirine and 
maraviroc exposure, including a role for metabolism of dapivirine in mucosal tissues, are 
unknown. A small subset of P450 isozymes are responsible for the phase I metabolism of 
70-80% of all clinically used drugs, including maraviroc and other antiretrovirals used to 
treat HIV [6]. The P450 superfamily of enzymes are heme-containing monooxygenases 
that increase the hydrophilicity of their substrates, facilitating their clearance [7]. Further, 
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P450-dependent metabolism plays a major role in drug-drug interactions and can result in 
the formation of metabolites that exhibit toxicity. Phase II drug metabolism that is 
mediated by the UGT family of enzymes transfers a glucuronic acid moiety onto the 
substrate, further facilitating their elimination.  
P450 enzymes are primarily expressed in the liver, which is the major site of oral 
xenobiotic metabolism; however, it is unknown whether drugs applied topically to 
vaginal and colorectal tissues, such as topical microbicides used in HIV PrEP, are 
metabolized locally. Topically applied drugs are unlikely to encounter the liver, and as 
such local metabolism would likely be a primary mediator of the pharmacokinetics of 
these drugs. Further, it is unclear whether a drug would be metabolized similarly if it 
were administered orally versus topically. In the present study, we demonstrate for the 
first time that P450 isozymes are expressed and active in vagina and colon. In addition, 
our findings indicate that metabolism of dapivirine and maraviroc differs between 
colorectal and vaginal tissues, potentially resulting in differential drug exposure. 
Collectively, these data provide novel insight that can be leveraged in interpreting HIV 
PrEP clinical pharmacology data and in developing drugs that will be administered 
topically to vaginal and/or colorectal tissue including antiretrovirals to be used in HIV 
PrEP.  
 
Materials and Methods 
Materials 
Dapivirine, dapivirine-d11, sulforaphane, and maraviroc were obtained from Toronto 
Research Chemical (Toronto, Ontario, Canada). Furafylline, sulfaphenazole, (+)-N3-
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benzylnirvanol, quinidine, and ketoconazole were obtained from Sigma-Aldrich (St. 
Louis, MO) and 2-phenyl-2-(1-piperidenyl) propane (PPP) purchased from Santa Cruz 
Biotechnology, Inc (Santa Cruz, CA).  Optima liquid chromatography/mass spectrometry 
grade water, acetonitrile, and formic acid were obtained from Thermo Fisher Scientific 
(Pittsburg, PA). 
Metabolism Assays 
All experiments were performed in Fisherbrand Siliconized Low-Retention 
Microcentrifuge Tubes (Thermo Fisher Scientific). Dapivirine (10 µM) was incubated 
with human liver microsomes (50 donor pool, Xenotech, LLC, Lenexa, KS),  cDNA-
expressed individual human CYPs (Supersomes™, BD Biosciences, San Jose, CA, CYP 
-1A2, -2A6, -2B6, -2C8, -2C9, -2C19, -2D6, -3A4, -3A5) or UGTs (Supersomes™, BD 
Biosciences, UGT1A1, -1A3, -1A4, -1A6, -1A7, -1A8, -1A9, -1A10, -2B4, -2B7, -2B15, 
-2B17). Final concentrations were as follows: human liver microsomes at 1 mg/mL, 
P450s at 10 pmol/mL, and UGTs at 0.2 mg/mL. Human liver microsomes or CYPs were 
combined with dapivirine in 100 mM potassium phosphate buffer, pH 7.4, and incubated 
for 5 min in a 37 °C water bath.  Reactions were initiated by the addition of a NADPH-
regenerating system (BD Biosciences) and allowed to proceed for 30 min at 37 °C. For 
inhibition studies, small molecule inhibitors were prepared as 500x solutions in DMSO 
and preincubated with the human liver microsomes in potassium phosphate buffer with 
the NADPH-regenerating system for 5 min at 37 °C. Inhibitors used were: furafylline (20 
μM) for CYP1A2, 2-phenyl-2-(1-piperidenyl) propane (30 μM) for CYP2B6, 
sulfaphenazole (20 μM) for CYP2C9, (+)-N3-benzylnirvanol (10 μM) for CYP2C19, 
quinidine (1 μM) for CYP2D6, and ketoconazole (1 μM) for CYP3A4/5. After the 
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addition of dapivirine, the reactions were allowed to proceed for 30 min at 37 °C. For 
reactions containing UGTs, the enzymes were combined with dapivirine in UGT reaction 
mix (Tris buffer, pH 7.5, alamethicin, and MgCL2; BD Biosciences) and incubated for 5 
min in a 37 °C water bath before initiating the reaction with 2 mM UDPGA. Reactions 
were allowed to proceed for 60 min at 37 °C and the total reaction volumes were 100 µL. 
After incubations, reactions were quenched with 100 µL acetonitrile, incubated for 10 
min at 4 °C, and the proteins removed by centrifugation at 3000g for 10 min at 4 °C. The 
supernatant was dried at 65 °C under vacuum pressure and the resulting residue 
reconstituted in 100 µL methanol for uHPLC-MS/MS analysis. Reactions carried out 
with liver microsomes from different species were carried out similar to reactions using 
human liver microsomes. Microsomes from BALB/C mice (male, pool of 800), CD-1 
mice (male, pool of 1,000), Sprague-Dawley rat (male, pool of 433), New Zealand rabbit 
(male, pool of 8), rhesus monkey (male, pool of 6), cynomolgus monkey (male, pool of 
800), Sinclair minipig (male, pool of 3), Hartley albino guinea pig (male, pool of 50), 
golden Syrian hamster (male, pool of 100), and beagle dog (male, pool of 8) were 
obtained from Xenotech. 
Ultra high performance liquid chromatography mass spectrometry (uHPLC-MS) 
A uHPLC-MS assay was developed for the quantification and identification of dapivirine 
metabolites, using a Dionex Ultimate 3000 uHPLC system coupled to a TSQ Vantage 
Triple Stage Quadrupole mass spectrometer (Thermo Fisher Scientific). Compounds were 
separated using a Polaris 5 C18-A column (5 µm, 100 x 2.0 mm, Agilent Technologies, 
Santa Clara, CA) at a flow rate of 0.4 mL/min. Solvent A was 0.1% formic acid in H2O 
and solvent B was 0.1% formic acid in acetonitrile. The gradient used is as follows: from 
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0% B to 50% B from 0.0-9.0 min, 50% B to 100% B from 9.0 min to 9.3 min, held at 
100% B until 12.3 min, from 100% B to 0% B from 12.3 to 13.3 min, and held at 0% B 
until 16.3 min. In MS/MS mode, metabolites were detected in positive ion mode as m/z = 
346.4 (monohydroxy dapivirine), 362.4 (dihydroxy dapivirine), 506.4 (glucuronidated 
dapivirine), and 522.4 (glucuronidated monohydroxy dapivirine). In selected reaction 
monitoring mode, fragment ions were detected in positive ion mode using the following 
transitions (Q1Q3): dapivirine (m/z 330.4158.4); M1 (m/z 346.4316.0); M2 (m/z 
346.4185.0); M3 (m/z 346.4174.0); M4 (m/z 346.4119.0); M5 (m/z 
362.4171.0); M6 (m/z 362.4332.0); M7 (m/z 506.4330.4); M8 (m/z 
522.4316.0); M9 (m/z 522.4346.4); M10 (m/z 522.4312.0); and M11 (m/z 
522.4346.6).   
The assay used to detect maraviroc metabolites used the same uHPLC and mass 
spectrometer system as the dapivirine assay and a uHPLC BEH C8 column (1.7 µm, 2.1 
x 100 mm, Waters, Milford, MA). Solvent A was 0.1% formic acid, 5% acetonitrile, and 
95% H2O and solvent B was 0.1% formic acid, 95% acetonitrile, and 5% H2O.  The 
gradient started at 0% B and increased to 10% B over 1.1 min, 14.3% B at 10.0 min, 25% 
B at 15.0 min, held at 25% B for 1 min, then brought down to 0% B at 16.1 min and held 
at 0% B for 0.9 min. Transitions for selected reaction monitoring were identical to those 
used in a previously reported assay [8]. 
Tissue Biopsy Culture 
Healthy subjects were recruited for tissue donation after providing written informed 
consent for participation in a protocol approved by the institutional review board of Johns 
Hopkins Medical Institutions. Each colorectal tissue donor provided 30 biopsies 
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(approximately 25 mg each) and each vaginal donor provided 5 biopsies (approximately 
25 mg each). Donor information is presented as sex and age: colorectal donors were 
female 49 years old, male 24 years old, and female 28 years old (denoted as colon 1, 
colon 2 and colon 3, respectively) while vaginal donors were female 27 years old, female 
27 years old, and female 28 years old (vagina 1, vagina 2 and vagina 3, respectively). The 
third colon and third vagina samples were obtained from the same individual. Upon 
collection, biopsies were placed into RPMI 1640 medium (Corning Life Sciences, 
Tewksbury, MA) supplemented with 10% heat inactivated fetal bovine serum, penicillin-
streptomycin, and L-glutamine and stored on ice for transport. The medium was replaced 
with fresh medium containing the appropriate treatment: methanol (vehicle control, 
0.1%), dapivirine (10 µM), sulforaphane (25 µM), or maraviroc (10 µM). After 
incubation for 6, 12, or 24 hours at 37 °C in a 5% CO2 humidified environment, culture 
medium was collected, dried at 65 °C under vacuum, and the residue reconstituted in 100 
µL methanol for uHPLC-MS/MS analysis. 
Primary Human Hepatocyte Culture 
Primary human hepatocytes were obtained from Xenotech. Donor information is 
presented as lot number, viability, sex, and age: 1152, 79.9%, female, 69; 1155, 74.7%, 
female, 43; 1157, 77.9%, female, 59 (denoted as hepatocyte 1, hepatocyte 2, and 
hepatocyte 3, respectively). Upon arrival, the shipment medium was aspirated and 
replaced with William’s medium E (Invitrogen) supplemented with 10% fetal bovine 
serum, 1% penicillin-streptomycin, and 1% L-glutamine. Hepatocytes were incubated 
overnight at 37 °C in a 5% CO2 humidified environment. The medium was replaced with 
fresh medium containing the appropriate treatment: methanol (vehicle control, 0.1%) or 
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dapivirine (10 µM) and cells were incubated for 6, 12, or 24 hours 37 °C in a 5% CO2 
humidified environment. RNA was isolated as described below. 
RNA Isolation, Endpoint PCR, and qRT-PCR Analysis 
Immediately after culture medium was removed, tissue biopsies or hepatocytes were 
immersed in TRIzol® (Life Technologies, Grand Island, NY) and RNA isolated following 
the manufacturer’s instructions. RNA was quantitated spectrophotometrically, and 2 µg 
of each used to synthesize cDNA using a Maxima First-Strand cDNA Synthesis Kit 
(Thermo Fisher Scientific) for use in endpoint reverse transcriptase PCR or qRT-PCR. 
For qRT-PCR, a standard curve was generated using glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) PCR products cloned into pJET1.2/blunt cloning vectors 
(Thermo Fisher Scientific). Primers used are presented in Table 1. Endpoint reverse 
transcriptase PCR was run using PCR Master Mix (2X) (Thermo Fisher Scientific), with 
the following thermal cycling conditions: 95 °C for 1 min, followed by 30 cycles of 95 
°C for 30 s, 60 °C for 30 s, and 72 °C for 1 min, and a final extension step of 72 °C for 5 
min. Products were analyzed via 1% agarose gel electrophoresis and visualized with 
SYBR® Safe DNA Gel Stain (Life Technologies). qRT-PCR was run using Maxima 
SYBR Green qPCR Master Mix (Thermo Fisher Scientific), with the following thermal 
cycling conditions: 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s, 60 °C for 
30 s, and 72 °C for 30 s. GAPDH was used for normalization of mRNA levels. 
Protein Isolation and Immunoblotting Analysis 
Biopsies were washed once in 500 µL phosphate buffered saline (PBS) and homogenized 
on ice in cell lysis buffer (Cell Signaling Technology, Danvers, MA) containing Halt 






Role Primers (5'3') Coordinates 
GAPDH NM_002046.3 Forward CTTCTTTTGCGTCGCCAGCCGA 62-83 
Reverse CACGACGTACTCAGCGCCAGC 390-370 
CYP1A1 NM_000499.3 Forward GTACCTCAGCCACCTCCAAGAT 88-109 
Reverse GCTCCTGCAACGTGCTTATC 632-651 
CYP1A2 NM_000761.3 Forward CATCCCCCACAGCACAACAAGGG 1219-1241 
Reverse CAGTTGATGGAGAAGCGCAGCC 1593-1614 
CYP2B6 NM_000767.4 Forward GTCGACCCATTCTTCCGGGGAT 317-338 
Reverse GAAGAGCTCAAACAGCTGGCCGAA 644-667 
CYP2C19 NM_000769.1 Forward TGGAGAAGGAAAAGCAAAACCAAC 812-835 
Reverse GGTTGTGCCCTTGGGAATGAGG 1137-1158 
CYP2E1 NM_000773.3 Forward ACCCAAGGCCAGCCTTTCGAC 514-534 
Reverse TCCACGAGCAGGCAGTCGGT 829-848 
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CYP3A4 NM_017460.5 Forward GGAAAAGTGTGGGGCTTTTATGATGG 307-333 
Reverse GCCTGTCTCTGCTTCCCGCC 589-608 
CYP3A5 NM_000777.3 Forward TTCACCATGACCCAAAGTACTGGAC 1304-1321 
Reverse TAACTCATTCTCCACTTAGGGTTCC 1591-1615 
PXR NM_022002.2 Forward CAAGCGGAAGAAAAGTGAACG 540-560 
Reverse CTGGTCCTCGATGGGCAAGTC 961-981 
 
Table 1. Primers used for qRT-PCR for P450 
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phenylmethanesulfonylfluoride (Sigma-Aldrich) using disposable pellet mixer pestles 
attached to a pestle motor (VWR International, Radnor, PA). Samples were centrifuged 
for 10 min at 3000 g, 4 °C and the resulting supernatant was stored at -20 °C. Protein 
concentrations were determined using a Pierce® BCA Protein Assay Kit (Thermo 
Scientific), following the manufacturer’s instructions. For immunoblots, 10 µg of each 
sample were loaded onto 10% or 12% Mini-PROTEAN® TGX™ Precast Gels (Bio-Rad, 
Hercules, CA) for separation via SDS-polyacrylamide gel electrophoresis. Proteins were 
transferred onto 0.2 µm pore nitrocellulose membranes (Life Technologies) and blotted 
with commercially available antibodies. Antibodies for CYP -2B6, -2C9, -2C19, -3A4, 
and -3A5 were obtained from BD Biosciences, anti-CYP2D6 was obtained from 
Xenotech. Anti-β-actin was used for normalization and was obtained from Cell Signaling. 
Proteins were visualized using SuperSignal West Dura Chemiluminescent Substrate 
(Thermo Fisher Scientific) according to the manufacturer’s protocol and imaged with a 
Carestream 4000R system. Blots were stripped with ReBlot Plus Strong Antibody 
Stripping Solution (Millipore, Billerica, MA), then blotted with different antibodies 
following confirmation of antibody stripping. 
 In situ Extract Preparation 
For analysis of in situ metabolite concentrations the tissue biopsies were washed with 
PBS 3 times prior to homogenizing in 500 µL ethyl acetate. The solution was dried at 65 





All data presented are means ± S. E. from three independent experiments. Two-tailed 
unpaired t tests were performed to compare datasets, and p ≤ 0.05 was considered 




Cytochrome P450 Expression in Mucosal Tissues that are Sites of HIV Infection 
 The ability of the colorectal and vaginal mucosa to biotransform xenobiotics has not 
been clearly defined; thus the expression of P450 isozymes found to metabolize HIV 
antiretroviral drugs was explored in these tissues. Vaginal and colorectal mRNA 
expression of P450s that play a prominent role in drug metabolism was examined through 
quantitative reverse transcriptase PCR (qRT-PCR). Expression of CYP1A1, -1A2, -2B6, 
-2C19, -2E1, -3A4, and -3A5 mRNA was detected in all samples (Figure 1A). 
Comparing the expression levels of these mRNAs in colorectal tissue to those of the 
vaginal tissue samples revealed that CYP3A5 mRNA levels were 4- (p-value = 0.04) fold 
higher in colorectal tissues. Expression was also probed on the protein level via 
immunoblotting using cell lysates isolated from the vaginal and colorectal biopsies 
(Figure 1B). Prior to screening, we verified that all of the antibodies were able to detect 
the cDNA expressed P450 isozymes that they were designed to target (data not shown). 
While CYP2B6, -2C19, -3A4, and -3A5 were readily detected in both tissue types, 
CYP1A2, -2A6, -2C9, and -2D6 were not. These results were consistent when comparing 




Figure 1. Expression of P450 mRNA and protein in colorectal and vaginal tissues. A. 
Quantification of mRNA expression levels of P450s (n=6) in colorectal and vaginal 
tissue. B. Immunoblots of P450 isozymes in protein lysates isolated from vaginal and 
colorectal tissue biopsies. C=colon donor, V=vagina donor. Colon 3 and vagina 3 are 









individual. Additionally, protein expression of CYP2B6, -2C19, and -3A4 was markedly 
higher in vaginal tissue than in colorectal. 
Maraviroc Metabolism by Colorectal and Vaginal Tissues 
 In order to probe the P450 activity in the mucosal tissues, colorectal and vaginal 
biopsies were obtained from healthy human donors for maraviroc treatment, followed by 
metabolite detection using uHPLC-MS/MS. We have previously demonstrated that 
maraviroc is a substrate of CYP3A4/5 [8], identifying 6 monooxygenated metabolites 
(M1-M6), 4 dioxygenated metabolites (M7-M10), and 2 glucuronidated metabolites 
(M11, M12) in human liver microsomes, plasma, and urine. Maraviroc is also being 
tested for use as a topical microbicide for HIV PrEP. After 24 hours of maraviroc 
treatment, colon tissue from all three donors produced a monooxygenated metabolite that 
was detectable in both the culture medium and in situ (Figure 2A and 2B). In contrast, of 
the two vaginal tissue donors that were treated with maraviroc, one produced this same  
monooxygenated metabolite (as measured in both culture medium and in situ) while the 
other did not (Figure 2C-2F). 
Identification of Dapivirine Metabolites 
Since dapivirine is under development as a topical microbicide for HIV PrEP we sought 
to determine whether dapivirine is also metabolized in the mucosal tissues to which it 
would be applied; however, since the metabolism of dapivirine has yet to be reported, we 
began our studies by using human liver microsomes to identify potential metabolites of 
dapivirine and to develop our uHPLC-MS methods for qualitatively detecting dapivirine 
and dapivirine products. Dapivirine (m/z = 330.4) was incubated with human liver 




Figure 2. Representative chromatograms depicting metabolism of maraviroc by 
colon and vagina tissue biopsies. Biopsies were incubated with maraviroc (10 µM) for 
24 hours at 37 °C. After incubation, the medium was collected and biopsies were 
homogenized in ethyl acetate. Medium and homogenates were analyzed via uHPLC-
MS/MS in selected reaction monitoring mode. A. Colon 3 biopsy medium. B. Colon 3 
biopsy in situ. C. Vagina 2 biopsy medium. D. Vagina 2 biopsy in situ. E. Vagina 3 










analyzed using uHPLC-MS/MS in product ion mode. In this manner, four 
monooxygenated (m/z = 346.4), two dioxygenated (m/z = 362.4), and five glucuronidated 
(m/z = 506.4 and m/z = 522.4) metabolites were identified. The monooxygenated 
metabolites were designated M1-M4, dioxygenated products M5-M6 and glucuronides 
M7-M11. No additional analytes corresponding to metabolites were detectable above 
background. Figure 3 shows the chromatograms for these metabolites that were obtained 
using uHPLC-MS/MS performed in selected reaction monitoring mode. Transitions for 
each metabolite were identified from the corresponding MS/MS fragmentation spectra 
and are detailed under Materials and Methods. Since NADPH is required for P450 
activity and UDPGA (uridine diphosphate glucuronic acid) is required for UGT activity, 
it was possible to confirm which biotransformations were catalyzed by each enzyme class 
in the human liver microsomal system. When the reaction contained only NADPH, M1 
was the most abundant metabolite and only products M1-M6 were detected. Reactions  
containing dapivirine in the presence of only UDPGA produced metabolite M7 as the 
sole detectable metabolite while formation of M8-M11 required incubation with both 
NADPH and UDPGA. In reactions that were performed in the absence of either NADPH 
or UDPGA no oxygenated or glucuronidated products, respectively, were detected. These 
data demonstrate that metabolites M1-M6 are CYP-dependent, M7 is UGT-dependent, 
and that the formations of M8-M11 are catalyzed by both P450s and UGTs acting in 
concert. Of the glucuronides, M7 and M11 are the most abundant metabolites.  
In order to elucidate the chemical structures of each metabolite, the MS/MS spectra were 
analyzed. Potential structures and proposed origins of fragment ions for the mono- and 




Figure 3. Extracted ion chromatograms showing the transitions used to monitor 
dapivirine metabolite formation. Dapivirine (10 µM) was incubated with human liver 
microsomes (1 mg/mL) for 30 min at 37 °C in the presence of a NADPH-regenerating 
system. Fragmentation spectra were used to derive the following transitions (Q1Q3): 
M1 (m/z 346.4316.0); M2 (m/z 346.4185.0); M3 (m/z 346.4174.0); M4 (m/z 
346.4119.0); M5 (m/z 362.4171.0); M6 (m/z 362.4332.0); M7 (m/z 
506.4330.4); M8 (m/z 522.4316.0); M9 (m/z 522.4346.4); M10 (m/z 




Figure 4. Fragmentation analysis of MS/MS spectra for M1-M6. Human liver 
microsomes (1 mg/mL) were incubated with 10 µM dapivirine for 30 min at 37 °C in the 
presence of a NADPH-regenerating system. Metabolites were detected and fragmented 
using uHPLC-MS/MS in product ion mode. From left to right, then top to bottom are M1, 




144.2 m/z found in the spectrum of metabolite M1 are proposed to originate from the loss 
of C2H6, C9H7N3O, and C12H14N2O, respectively. Fragments of 299.2, 185.1, and 156.1 
m/z in MS/MS spectrum collected for product M2 are due to the loss of C2H7O, 
C10H11NO, and C10H12N3O, respectively. For M3, we propose that fragments 186.2, 
174.1, 161.1, and 135.1 m/z derive from the loss of C10H12N2, C12H14N, C12H13N2, and 
C11H7N4O, respectively. The spectrum of M4 has fragments 146.0, 135.8, and 119.2 m/z, 
corresponding to losses of C10H8N4O, C12H10N4, and C14H15N2O, respectively.  
Metabolite M5 has ions of 285.0, 171.1, and 156.0 m/z, proposed to result from losses of 
C3H9O2, C8H7N4O2, and C9H10N4O2, respectively. Lastly, the fragmentation spectrum of 
M6 shows ions of 332.1, 328.2, 156.1, 144.0, and 131.8 m/z, which are proposed to 
originate from the loss of H2O2, C2H6, C9H10N4O2, C11H12N3O2, and C12H14N4O. Quality 
spectra were difficult to obtain for M7-M11, as for each of these products the glucuronic 
acid dissociated from the parent ion in the mass spectrometer; however, the remainder of 
the molecule did not fragment to detectable ions.  Since M7 is only dependent on 
UDPGA, it must be the result of the direct glucuronidation of dapivirine. It is known that 
O- and N-glucuronidation are the most common glucuronidation reactions [9], thus the 
glucuronic acid moiety of M7 is most likely located on one of the secondary amines or a 
nitrogen atom within the pyrimidine ring. The other four glucuronides result from 
glucuronidation of monooxygenated metabolites M1-M4, although it remains to be 
determined whether the glucuronide conjugation to these metabolites occurs on the 
oxygen inserted by the CYP or on a nitrogen atom already present in dapivirine. 
In order to further probe which sites of dapivirine were oxygenated by P450 enzymes 




Figure 5. Determining which dapivirine metabolites are modified on the mesitylene 
ring. Relative contributions to total metabolite profile when dapivirine or dapivirine-d11 
are incubated with  human liver microsomes (1 mg/mL) for 60 min at 37 °C in the 
presence of an NADPH-regenerating system and UDPGA. All metabolites were detected 









replacing the 11 hydrogens on the mesitylene ring. Due to the isotope effects, oxygen 
insertions occurring at the deuterated locations proceed at a slower rate, resulting in 
decreased abundance of the oxygenated metabolites as compared to parallel assays 
performed using the non-isotopically labeled dapivirine. As can be seen in Figure 5, the 
relative abundances of M1 (p-value = 0.003), M2 (p-value = 0.014), and M5 (p-value = 
0.018) were decreased when the deuteriums are present. Taken together, the 
fragmentation analyses and dapivirine-d11 studies indicate that M1 and M2 each result 
from monooxygenation of one of the three methyl groups of the mesitylene ring while 
M3 appears to be oxygenated on one of the four carbons of the benzene ring, M4 is 
oxygenated at the nitrogen connecting the mesitylene to the pyrimidine, M5 is 
oxygenated on two of the mesitylene carbons, and M6 is oxygenated on one mesitylene 
carbon and a secondary amine. 
Enzymes Responsible for Dapivirine Metabolism 
In order to determine which P450 isozymes were responsible for producing the observed 
dapivirine metabolites, metabolism assays were carried out using individual cDNA-
expressed CYP1A2, -2A6, -2B6, -2C8, -2C9, -2C19, -2D6, -3A4, and -3A5 (Figure 6A). 
M1 was primarily produced by CYP1A2, -2B6, -2D6, -3A4, and -3A5 and to a lesser 
extent by CYP2C8 and -2C19. M2 had a similar profile, although CYP2A6 and -2D6 
were minor contributors to the formation of this metabolite. M3 was primarily produced 
by CYP3A4 and -3A5, with minor production by CYP1A2, -2C8, -2C19, and -2D6. 
Formation of M4 was primarily catalyzed by CYP1A2 with all of other CYP isozymes 
tested being minor contributors. M5 was produced solely by CYP3A5 and M6 was most 
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abundant in the incubations containing CYP3A4 with CYP2D6 and -3A5 as lesser 
contributors. 
 The relative contributions of each P450 to overall formation of these metabolites 
in vitro was explored by performing human liver microsome metabolism assays in the  
presence and absence of small molecule inhibitors of the individual P450 isozymes 
(Figure 6B). There were no statistically significant differences in the formation of any of 
the metabolites when furafylline, which inhibits CYP1A2, nor sulfaphenazole, which 
inhibits CYP2C9, nor when quinidine, which inhibits CYP2D6, were present. When a 
CYP2B6 inhibitor, 2-phenyl-2-(1-piperidenyl), was present, the production of M2, M3, 
and M4 was decreased. An inhibitor for CYP2C19, benzylnirvanol, resulted in decreased 
production of M3 and M6. The greatest decreases in M2-M6 production were observed 
when ketoconazole, an inhibitor of CYP3A4/5, was present. In addition, M1 production 
was also decreased in the incubations containing ketoconazole.  
 Relative contributions of UGT isozymes to the formation of glucuronides M7-
M11 were also probed (Figure 7). Dapivirine was incubated with human liver 
microsomes in the presence of a NADPH-regenerating system, so that all P450-mediated 
metabolites were produced. The reaction product was then incubated with individual 
cDNA-expressed UGT1A1, -1A3, -1A4, -1A6, -1A7, -1A8, -1A9, -1A10, -2B4, -2B7, -
2B15, and -2B17.  M7 was primarily produced by UGT1A4 and -2B7, with UGT1A1 as 
a minor producer. UGT1A1 was the major contributor to M8 formation and UGT1A3, -
1A4, -2B7, and -2B15 were minor contributors. M9 was most abundant in the incubations 
containing UGT1A7, -1A9, and -2B7 while UGT1A6, -1A8, -1A10, and -2B4 were 







Figure 6. Formation of dapivirine metabolites by P450 isozymes. A. Ability of 
individual cDNA-expressed P450s to produce dapivirine metabolites. P450 isozymes (10 
pmol/mL) were incubated individually with dapivirine (10 µM) for 30 min at 37 °C in the 
presence of an NADPH-regenerating system. B. Inhibition of individual P450s in order to 
examine dapivirine metabolite production when multiple P450 isozymes are present. 
Human liver microsomes (1 mg/mL) were preincubated with small molecule P450 
inhibitors in the presence of a NADPH-regenerating system for 5 min at 37 °C prior to 
the addition of dapivirine (10 µM), then incubated for 30 min at 37°C. Dapivirine 
metabolites were detected via uHPLC-MS/MS in selected reaction monitoring mode.  
















Figure 7. Ability of individual UGTs to produce dapivirine metabolites. For the UGT 
incubations, dapivirine (10 µM) was incubated with human liver microsomes (2 mg/mL) 
for 30 min at 37 °C in the presence of NADPH-regenerating system, the reactions were 
quenched and dried under vacuum followed by resuspension of the residue in methanol 
for use as a substrate for UGTs. UGT (0.2 mg/mL) incubations were for 60 min at 37 °C 
in the presence of UDPGA. Dapivirine metabolites were detected using uHPLC-MS/MS 








extent by UGT1A3 and -1A4. Lastly, UGT1A1 was the major contributor to M11 
production and UGT1A3, -1A7, -1A8, -1A9, -2B4, and -2B7 were minor contributors. 
Dapivirine Metabolism by Vaginal and Colorectal Tissues 
Following the identification of the metabolites that result from dapivirine metabolism and 
the demonstration that mucosal tissues produce maraviroc metabolites, dapivirine was 
similarly used as a probe for enzymatic activity in mucosal tissues (Figure 8). The 
biopsies were submerged in culture medium and following 24 hours of dapivirine 
treatment, monooxygenated metabolites M1 and M4 as well as glucuronides M7 and 
M11 were consistently detected in medium that was incubated with colorectal biopsies. 
However, only monooxygenated metabolites M1, M2, and M4 could be detected in the 
medium used to treat vaginal biopsies. Tissue biopsies were also homogenized in ethyl 
acetate in order to detect metabolites in situ. M1, M2, M3, M4, M7, and M11 were all 
detected within colon tissues while only M1, M2, M3, and M4 were present in vagina  
tissue. These differences were consistent in the matched colon and vagina biopsy samples 
from the same donor. In addition, no metabolites were identified following incubation 
with colorectal or vaginal tissue that were not present in the human liver microsome or 
cDNA-expressed enzyme systems. Taken together, these data are a demonstration of 
P450 activity in both colon and vagina tissues, whereas UGTs that catalyze the formation 
of dapivirine and dapivirine metabolite glucuronic acid conjugates may be active in colon 
but not vagina.  
 Since drug-induced changes in P450 expression are a major mechanism of drug-
drug interactions, dapivirine treatment dependent P450 mRNA changes were explored in 









Figure 8. Representative chromatograms depicting metabolism of dapivirine by 
colon and vagina tissue biopsies. Biopsies were incubated with dapivirine (10 µM) for 
24 hours at 37 °C. After incubation, the medium was collected and biopsies were 
homogenized in ethyl acetate. Medium and homogenates were analyzed via uHPLC-
MS/MS in selected reaction monitoring mode. A. Colon 3 biopsy medium. B. Colon 3 














limited tissue availability as a result of the marked difference in the maximum amount of 
tissue that could reasonably be collected from the colon versus the vagina. Colon donor 1 
(age 49, female) demonstrated a 3-fold decrease of CYP2B6 and a 4-fold decrease in  
CYP2E1 mRNA levels following 24 hours of dapivirine treatment and no changes in 
CYP1A1, -1A2, -2C19, -3A4, nor -3A5 mRNA, as compared to the vehicle-treated 
control tissue that was cultured in parallel with the drug-treated samples. The second 
colon donor (age 24, male) exhibited a 4-fold, 5-fold, 5-fold and 7-fold increase in 
CYP1A2, CYP2C19, CYP2E1 and CYP3A4 mRNA levels, respectively, after 24 hours, 
and no changes in mRNA levels of CYP1A1, -2B6, nor -3A5.The third donor (age 28, 
female) demonstrated a 2.5-fold increase in CYP3A4 mRNA levels with no other 
changes. It was previously reported that etravirine modulates CYP3A4 expression in a 
pregnane x receptor (PXR)-dependent manner [10]. When biopsies from the third donor  
were incubated in the presence of both dapivirine and sulforaphane, a PXR inhibitor, the  
2.5-fold increase in CYP3A4 mRNA observed with dapivirine alone was abrogated (Fig 
9D). With this in mind, PXR mRNA expression in the colon tissues was measured and 
showed positive correlation with the observed changes in CYP3A4 mRNA, indicating 
that there may be a relationship between PXR levels and dapivirine-treatment dependent 
CYP3A4 mRNA expression changes in colon tissue (Figure 9E). 
Dapivirine dependent induction of CYP3A4 mRNA in primary human hepatocytes 
The potential for dapivirine to induce CYP3A4 expression was further explored by 
incubating primary human hepatocytes with dapivirine for increasing amounts of time 
(Fig 10). Hepatocyte donors 1 and 3 showed no significant change in CYP3A4 mRNA 




Figure 9. Dapivirine-treatment mediated changes in colon P450 mRNA levels and 
the relationship to basal PXR expression. Colon biopsies (A-C) were incubated with 
dapivirine (10 µM) for 24 hours at 37 °C. Biopsies from colon 3 were also incubated in 
the presence of 25 µM sulforaphane (D). After incubation, RNA was isolated and used in 
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Figure 10. Dapivirine dependent induction of CYP3A4 mRNA in one out of three 
hepatocyte donors. Dapivirine (10 µM) was incubated with primary human hepatocytes 
for 6, 12, and 24 hours at 37 °C. After incubation, RNA was isolated and used in qRT-

















12, and 24 hours, respectively. Hepatocyte donor 1 demonstrated 5-fold decrease in 
CYP2B6 mRNA at 6 hours, but the trend did not continue through extended incubation. 
Lastly, hepatocyte donor 3 showed 11.9-fold, 14.6-fold, and 14.1-fold decrease in 
CYP1A1 mRNA and 2.1-fold, 5.6-fold, and 7.3-fold decrease in CYP1A2 mRNA over 6, 
12, and 24 hours, respectively. 
Dapivirine metabolism by multiple animal species 
In order to determine which animal species would be the ideal model system for 
examining dapivirine metabolism, metabolism assays were carried out using liver 
microsomes from the following species: BALB/c mouse, Sprague-Dawley rat, New 
Zealand rabbit, rhesus monkey, cynomolgous monkey, CD-1 mouse, Sinclair minipig, 
Hartley albino guinea pig, golden Syrian hamster, and beagle dog. Reactions were carried 
out in the presence and absence of NADPH regenerating system (Figure 11). BALB/c 
mouse, Sprague-Dawley rat, and New Zealand rabbit displayed significantly greater  
production of M1 than humans (p-values 0.028, 0.001, and 0.035, respectively). Golden 
Syrian hamster deviated from the other animals in that there was no production of 
monohydroxylates M1-M3 in the presence of NADPH, but M1-M3 were all produced in 
the absence of NADPH. The rat, guinea pig, and beagle produced significantly larger 
amounts of M2 than humans (p-values 0.008, 0.014, and 0.049, respectively) and 
cynomolgous monkey and golden Syrian hamster produced significantly less M3 than 
humans (p-values 0.0009 and 0.0040, respectively). M4 production varied greatly, with 
rabbit, cynomolgous monkey, minipig, and hamster producing less than humans (p-
values 0.0010, 0.0004, 0.0340, and 0.0002, respectively) and guinea pig and beagle 





















Figure 11. Dapivirine metabolism by microsomes from multiple animal species. 
Dapivirine was incubated with liver microsomes (1 mg/mL) for 30 min at 37 °C in the 
presence or absence of a NADPH-regenerating system. Experiment performed in 
triplicate. Two-tailed unpaired student’s t tests were carried out to compare each animal 




statistically significant differences in M5 production. Lastly, rabbit produced less M6 
than humans (p-value 0.013) whereas rat, rhesus monkey, and cynomolgous monkey 
produced more (p-values 0.012, 0.022, and 0.010, respectively). Overall, CD-1 mouse is 
the only animal that did not display any statistically significant differences in dapivirine 
metabolism when compared to humans. 
 
Discussion 
Through an examination of dapivirine and maraviroc metabolism in colon and vagina 
tissues, the present study demonstrates, for the first time, P450 activity in both colon and 
vagina and UGT activity in colon. While dapivirine metabolism was consistent across 
donors, and maraviroc was metabolized in all colon donors, maraviroc was only 
metabolized in one of the two vagina biopsies treated. This hints at inter-individual 
differences in antiretroviral drug metabolism and disposition which will have to be 
explored further. While the relatively small number of samples employed in the current 
study is a potential limitation, these data lay the groundwork for future studies of drug 
metabolism in the vaginal and colorectal mucosa. Analyses of larger study populations 
will be required to gain a comprehensive understanding of tissue-specific 
biotransformation in these compartments. 
While the liver is the primary organ responsible for xenobiotic metabolism, when 
drugs are dosed orally, mucosal tissues may be important to the local metabolism of 
topical drugs used as microbicides. Previous studies have examined colorectal P450 
mRNA expression [11, 12]. These studies found that multiple members of the CYP2C, 
CYP2E, and CYP3A families are expressed on the mRNA and protein level in human 
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colon biopsy tissue, and that this expression may vary in different parts of the colon. 
There have also been studies that detect protein or mRNA expression of CYP1A, 
CYP2B, CYP2C, and CYP3A in cervical tissue [13-15].  However, enzymatic activity of 
P540s and other metabolizing enzymes in the colon and vagina has not yet been reported. 
Using qRT-PCR, the present study demonstrates differences in P450 mRNA expression 
levels between colon and vagina tissues, finding higher CYP1A2 and -2B6 mRNA in 
vagina and greater expression of CYP3A5 mRNA in colon. Immunoblots also revealed 
that protein expression of CYP2B6, -2C19, and -3A4 is higher in the vagina than in the 
colon. Interestingly, in colon samples, dapivirine stimulated increases in CYP3A4 mRNA 
levels that appeared to be positively correlated with basal PXR mRNA expression. PXR 
is a nuclear receptor that contributes to the transcriptional regulation of CYP3A4 [6] and 
we have previously demonstrated that etravirine, which is structurally similar to 
dapivirine, upregulates CYP3A4 mRNA expression in a PXR-dependent manner [10]. As 
such, PXR may play a role in mediating the dapivirine-dependent increases in CYP3A4 
mRNA levels in colorectal tissue that were observed here.   
The proposed scheme for P450-mediated metabolism of dapivirine is presented in Figure 
12. Both colon and vagina tissues were able to metabolize dapivirine, producing 
metabolites that were determined to be P450-mediated using human liver microsomes. 
This is a definitive demonstration of P450 activity in colorectal and vaginal tissues. 
Metabolites M1-M4 were produced by colon and vagina tissue biopsies, and the P450 
isozymes that we determined were responsible for the formation of these dapivirine 
metabolites were all found to be expressed in these same biopsies using immunoblotting. 




Figure 12. Proposed P450-mediated metabolism of dapivirine. 
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ring.  This may be due to constraints on substrate positioning within the active site of the 
P450 isozymes, which can be further examined through the use of molecular docking.  
 Incubations of dapivirine with individual cDNA-expressed P450s or human liver 
microsomes with small molecule inhibitors of individual P450s established which P450 
isozymes produce the observed metabolites of dapivirine. There is strong evidence for 
major contributions from CYP3A4 and -3A5, since human liver microsomes pre-
incubated with the CYP3A inhibitor ketoconazole exhibited significantly lower 
production of all oxygenated metabolites with the exception of M1. Production of M1 
was shown to be catalyzed by cDNA expressed CYP1A2, -2B6, -2D6, -3A4, and -3A5. 
Thus, even in the presence of chemical inhibition of CYP3A4/5 activity in human liver 
microsomes this metabolite may be formed by other microsomal P450 isozymes.  It was 
also noted that CYP1A2 appeared to be able to produce metabolite M4 in our cDNA-
expressed P450 assays; however, incubation of human liver microsomes with the 
CYP1A2 inhibitor furafylline did not result in a significant decrease in M4 levels. These 
data indicate that, while CYP1A2 may have the ability to form M4, this enzyme may not 
be a major contributor to the formation of this metabolite in a system where all hepatic 
microsomal P450 isozymes are present. Interestingly, while P450-dependent metabolites 
of dapivirine were detected in the culture medium collected following incubation with 
both vaginal and colorectal tissue as well as in situ in both tissues the UGT-dependent 
metabolites of this compound were only produced by colorectal tissue. This difference in 
metabolism may lead to differential rates of clearance between the two tissues.  
Further, our data indicate that metabolism of dapivirine and maraviroc by vaginal 
and colorectal tissue may vary from hepatic metabolism of these drugs.  The ideal 
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comparison to examine differences in hepatic and mucosal metabolism would be to 
compare human liver microsomes to microsomes isolated from the colorectal and vaginal 
mucosa. However, due to constraints on the amount of tissue that can be collected from 
living donors, neither colorectal nor vaginal microsomes were able to be isolated in large 
enough quantities to facilitate metabolism assays. Additionally, it is not feasible to collect 
liver tissue from living donors to be used as a direct comparison to the mucosal biopsies 
we have studied. A potential difference in metabolism of a drug dosed orally versus 
topically is particularly evident in the case of maraviroc since in the present study we 
observed a marked difference in metabolite formation by colorectal and vaginal tissues as 
compared to the metabolite profiles that we have previously described in plasma and 
urine of human subjects following oral administration of maraviroc [8]. As such, both 
tissue and hepatic biotransformation may need to be examined in working to gain a 
complete understanding of the clearance of antiretrovirals and other drugs being 
developed for both oral and topical administration. Since dapivirine is being developed 
for topical use only, metabolism by the tissue upon which dapivirine would be 
administered is likely to be the most relevant in understanding the biotransformation of 
this compound.  
In order to facilitate the success of HIV PrEP while concurrently avoiding 
selection for resistant strains of virus it is crucial that the factors that regulate the 
exposure to individual antiretrovirals be understood. While dapivirine is highly potent 
with an IC50 in the nanomolar range for both cell-free and cell-associated virus [16, 17], it 
has been shown that suboptimal concentrations of dapivirine can still lead to resistance 
[18]. Patient non-adherence is the most widely cited factor for lower than intended 
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concentrations of drugs, but drug metabolism must also be taken into account. If the 
metabolites are not pharmacologically active against HIV, individuals with high 
metabolic activity may experience decreased efficacy and select for resistant strains of 
virus. For instance, CYP3A5 which we have demonstrated here to be a major contributor 
to dapivirine metabolism, is highly polymorphic [19] and as such CYP3A5 genotype 
could potentially influence the vaginal and colorectal tissue exposure to dapivirine. 
Biotransformation of drugs may also produce toxic metabolites, as is the case with the 8-
hydroxy metabolite of efavirenz, another NNRTI [20]. Toxic metabolites formed locally 
by the vaginal and colorectal tissues have the potential to stimulate inflammation in the 
mucosa, whether from mucosal cell death or pathogenic bacteria displacing the 
commensal species, which may initiate the recruitment of immune cells and make 
establishment of HIV infection more likely [21]. While studies have already shown that 
dapivirine is not toxic to commensal vaginal Lactobacillus [22] this testing has not been 
performed for the dapivirine metabolites. To this end, now that the metabolites of 
dapivirine have been identified, future studies should include an analysis of the toxicity 
and pharmacologic activity of these compounds. Such studies will help to understand 
how inter-individual differences in metabolizing enzyme activity may contribute to 
differences in toxicity and efficacy across populations.  Because these dapivirine 
metabolites were previously unreported, reference standards were unavailable for 
development of a quantitative assay. The current qualitative assay serves the desired 
purpose of metabolite identification and preliminary characterization, and could be 
developed into a quantitative assay which would be required for studying the in vivo 
pharmacokinetics of dapivirine metabolites. 
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In summary, the studies described here examine the metabolism in vaginal and 
colorectal tissues of dapivirine and maraviroc, a NNRTI and an entry inhibitor, 
respectively, being developed for use as topical microbicides for HIV PrEP. P450 activity 
was demonstrated for the first time in vaginal and colorectal mucosal tissues and 
potential differences in P450 and UGT expression and activity between these two tissues 
were revealed. We anticipate that these data can be leveraged in order to inform the 
development of antiretroviral drugs as topical microbicides for HIV PrEP as well as a 
broader spectrum of drugs that may be developed for administration to vaginal and 
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Chapter 3: Identification and expression profiling of nucleoside kinases that activate 
tenofovir in tissues targeted by human immunodeficiency and hepatitis B virus 
 
Abstract 
Nucleoside reverse transcriptase inhibitors such as tenofovir are used to treat and prevent 
human immunodeficiency virus infections and to treat hepatitis B infections. These drugs 
must be phosphorylated intracellularly in order to become active within the tissue types 
targeted by these viruses; however the enzymes that modulate the activation of these 
drugs are unknown. Here we probed the expression of candidate nucleotide kinases in 
peripheral blood mononuclear cells, CD4+ cells, colorectal tissue, vaginal tissue, and liver 
tissue. We found that expression of adenylate kinase 2 and creatine kinases was markedly 
higher in colon tissues versus white blood cells and vaginal tissue. Knockdown of 
candidate nucleotide kinases also shows that adenylate kinase 2 and pyruvate kinases 
activate tenofovir in white blood cells and vaginal tissues whereas adenylate kinase 2 and 
creatine kinase muscle carry out the activation in colorectal tissues. Taken together, these 
data form an understanding of which enzymes are responsible for the activation of 









Antiretroviral therapies such as tenofovir (TFV) are used to decrease viral counts in 
individuals infected with human immunodeficiency virus (HIV), hepatitis B (HBV), or 
both [1]. These compounds are nucleoside based reverse transcriptase inhibitors (NRTIs) 
that require intracellular phosphorylation to their active forms, which are analogous to the 
natural nucleotide triphosphate substrates of viral reverse transcriptase [2]. However, 
HBV targets hepatocytes within the liver while HIV targets CD4+ cells. Drugs that are 
taken orally are subject to the first-pass effect, whereby a drug may be extensively 
metabolized in the liver and gastrointestinal tract before reaching the systemic 
circulation. While hepatic metabolism of drugs meant to treat HBV may result in drug 
activation within hepatocytes, drugs meant to treat HIV must proceed beyond the liver 
and gastrointestinal tract to be activated within CD4+ cells in the systemic circulation. 
Attempts to prevent the establishment of HIV infection have included topical application 
of antiretroviral therapies to the mucosal tissues of infection, which allows drugs to 
bypass the liver in order to reach the targeted CD4+ cells within the colon and vagina 
mucosa [3]. As such, the expression and activity of the endogenous kinases that 
phosphorylate tenofovir, thus influencing the efficacy of therapy, must be understood in 
the liver (HBV) and CD4+ T cells in circulation, in the colon and in the lower female 
genital tract (HIV).   
TFV is an analogue of adenosine 5’-monophosphate that needs to undergo two 
phosphorylation steps to achieve its active form, tenofovir diphosphate (TFV-DP) [4]. 
While TFV-DP has an exceptionally long intracellular half-life of ≥ 60  h, TFV itself is 
not orally bioavailable and must be given as the prodrug tenofovir disoproxil fumarate 
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[5]. Tenofovir disoproxil fumarate contains two ester groups to enhance oral 
bioavailability. These esters are believed to be removed as the prodrug is absorbed by the 
intestines and within the liver [6]. TFV can then be phosphorylated to tenofovir 
monophosphate (TFV-MP) and subsequently TFV-DP in hepatocytes or in CD4+ T cells. 
It has been shown that treating primary human hepatocytes and peripheral blood 
mononuclear cells (PBMCs), which contain CD4+ cells, in vitro with TFV can produce 
TFV-DP [7, 8].  
The adenylate kinase (AK) enzyme family is proposed to be responsible for the 
first phosphorylation step of TFV. Using subcellular fractions from a human T 
lymphoblast cell line, AK2 was shown to have potent kinase activity towards adefovir, a 
structural analogue of TFV,  in vitro while AK1 and AK3 were shown to have no 
demonstrable activity [9]. This study also showed phosphorylation of TFV in the same 
system, but only reported kinetic parameters for the phosphorylation of adefovir (KM = 
14.0 ± 2.8 mM and kcat = 6.8 ± 1.2 s-1). The remaining AK isozymes have not been tested. 
While the nucleotide diphosphate kinase enzyme family is proposed to be responsible for 
the second phosphorylation step [5], in vitro studies using purified enzymes disagree on 
the ability of NDPK to perform this step [10, 11]. Koch, et al., showed low activity 
towards TFV-MP (KM = 0.29 ± 0.03 mM and kcat = 0.12 ± 0.01 s-1), but Varga, et al., 
could not detect any NDPK activity towards TFV-MP.  However, both studies 
demonstrate potent TFV-MP phosphorylation activity by the creatine kinase (CK) 
enzyme family and lower yet efficient activity by the pyruvate kinase (PK) enzyme 
family. The CK family consists of a brain isoform (CKB), a muscle isoform (CKM), and 
two mitochondrial isoforms (CKMT1 and CKMT2) while the PK family has a liver/red 
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blood cell isoform (PKLR) and a muscle isoform (PKM). Koch, et al., reported kinetic 
parameters for CKB activity towards TFV-MP and indicated that CKM activity was 
similar (KM = 1.2 ± 0.20 mM, kcat = 400 ± 30 s-1), whereas Varga et al. only tested CKM 
and found lower activity (KM = 0.24 mM, kcat = 1.9 s-1). Both studies monitor activity by 
directly detecting TFV-DP using high performance liquid chromatography, and the CKB 
and CKM isoforms display 81% amino acid similarity, so the discrepancy likely arises 
from the higher assay temperature and presence of enzyme activators in Koch et al.’s CK 
assays. The mitochondrial CK isoforms, which show 63-67% amino acid similarity with 
the brain and muscle isoforms, have never been examined for activity towards tenofovir. 
Studies examining PK activity towards TFV-MP have only used rabbit PKM, with Koch 
et al. obtaining the kinetic parameters KM = 11 ± 3 mM and kcat = 6.8 ± 2.3 s-1. Varga et 
al. were unable to calculate KM, but assuming KM = 11 mM were able to calculate kcat = 
1.35 s-1 from the obtained reaction velocity of 0.112 s-1. Rabbit PKM has 97% amino acid 
identity with human PKM, thus the observed activity of rabbit PKM towards TFV is 
likely to be recapitulated with human PKM. However, this is less likely when considering 
human PKLR due to the 66% amino acid similarity between human PKM and human 
PKLR. Lastly, in vitro studies using purified enzymes show that guanylate kinase 1 
(GUK1) can activate amdoxovir, a guanine analogue anti-HIV drug in phase II clinical 
studies, but its potential to activate TFV is unknown [12]. The primary limitation of these 
in vitro studies is that they do not account for the presence of other potentially competing 
nucleotide kinases or the presence of enzyme expression and activity within the cells of 
clinical relevance.  
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Crystal structures and docking studies endeavored to provide explanation for the 
observed activity towards TFV [10, 11]. Co-crystallization and docking of TFV-MP with 
NDPK from the amoeba dictyostelium discoideum (60% sequence identity with human 
NDPK) showed that while TFV-MP binds in the natural substrate site, fewer Van der 
Waals and polar interactions are made as compared to the natural substrate. This may 
account for the significantly lower affinity of NDPK for TFV-MP versus ADP. 
Additionally, NDPK is known to act through a 3’-OH dependent mechanism, and since 
TFV-MP lacks this moiety, the near absence of NDPK activity towards TFV-MP appears 
supported. Co-crystallizations have not been carried out for the remaining enzymes. 
However, it is known that binding of the natural substrate ADP to rabbit CKM results in 
quenching of the protein’s intrinsic tryptophan fluorescence. Similar studies carried out 
on human CKM show that there is 5-fold less fluorescence quenching upon TFV-MP 
binding as compared to ADP binding. Docking of TFV-MP to Torpedo californicum CK 
shows that a key interaction between W228 and the magnesium-substrate complex is 
missing. Overall, these data support the observed weaker binding of TFV-MP versus 
ADP to CK enzymes. Lastly, docking of TFV-DP into a crystal structure of rabbit PKM 
co-crystallized with ATP shows that many of the identified enzyme-substrate interactions 
are preserved, supporting the observed PK activity towards TFV-MP. 
Transport proteins are also expected to impact intracellular concentrations of TFV 
and its metabolites [6]. Organic anion transport family 1 and 3 (OAT1, OAT3) have been 
shown to mediate the uptake of tenofovir when overexpressed in human cell lines [13, 
14] and the prodrug of TFV interacts with the organic cation transporters (OCT) [15]. 
Multiple drug resistance-associated protein 4 (MRP4) mediates the efflux of tenofovir in 
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a human ovarian carcinoma cell lines [16, 17]. Additional members of the multiple drug 
resistance-associated protein family (MRP), p-glycoprotein (MDR1), breast cancer 
resistance protein (BCRP), and the equilibrative nucleoside transporters (ENT) have also 
been implicated in efflux of other nucleoside monophosphate analogues [18-20]. 
An understanding of the enzymes that modulate intracellular concentrations of 
TFV-DP is necessary for optimal use of the drugs in treating and preventing HBV and 
HIV infection. Knowledge of which enzymes activate the drugs in which tissues enables 
better modeling of the activity of TFV and may help to explain the clinical observation 
that TFV-DP is found in greater concentrations in colorectal than in vaginal tissues [21]. 
With this in mind, we aimed to determine whether each of the candidate nucleotide 
kinases are expressed in the tissues of relevance and use these data to examine which 
kinases are responsible for the activation of NRTIs in whole cell systems. Transport 
enzyme expression was also investigated in PBMCs, colon tissue, and vaginal tissue. 
PBMCs, colon tissue, vaginal tissue, and liver protein lysates were obtained from healthy 
human donors and probed via immunoblotting for protein expression to show that AK2, 
CKB, CKM, CKMT1, and CKMT2 are expressed in greater amounts in colon tissues 
versus vagina tissues and ENT1 and BCRP are expressed in colon and vagina tissues, but 
not in PBMCs. A direct liquid chromatography mass spectrometry assay was developed 
to simultaneously detect TFV, TFV-MP, and TFV-DP, was used with siRNA 
knockdowns to determine which kinases are responsible for TFV phosphorylation in 
whole cell systems. We show that, in PBMCs and vaginal tissues, AK2 and the two PKs 
are responsible for TFV activation, whereas colorectal tissue phosphorylation of TFV 
depend on AK2 and CKM. 
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Materials and Methods 
Materials 
Bovine serum albumin (BSA), NH4Cl and NaHCO3 were obtained from Sigma-Aldrich 
(St Louis, MO). Phosphate buffered saline (PBS) and ethylenediaminetetraacetic acid 
(EDTA) were obtained from Life Technologies (Carlsbad, CA). Molecular Biology 
Grade Water, Nuclease and Endotoxin Free, was purchased from Quality Biological, Inc. 
(Gaithersburg, MD). TFV was provided through the NIH AIDS Reagent Program 
(Germantown, MD), TFV-13C and TFV-MP were purchased from Moravek 
Biochemicals (Brea, CA) and TFV-DP was purchased from Toronto Research Chemical 
(Toronto, Ontario, Canada). Optima liquid chromatography/mass spectrometry grade 
water, acetonitrile, acetic acid, and ammonium hydroxide and high performance liquid 
chromatography grade ammonium acetate were purchased from Thermo Fisher Scientific 
(Waltham, MA). 
Isolation of RNA from PBMCs 
Healthy subjects were recruited for blood donation after providing written informed 
consent for participation in a protocol approved by the institutional review board of Johns 
Hopkins Medical Institutions. Whole blood was collected and subjected to PBMC 
isolation via Ficoll-Paque (GE Healthcare, Pittsburgh, PA), following the manufacturer’s 
instructions. Cells were them immersed in TRIzol® (Life Technologies) and the RNA 
isolated following the manufacturer’s instructions. RNA was quantitated 
spectrophotometrically. 
Quantitative reverse transcriptase PCR (qRT-PCR) analysis 
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Total RNA from the descending colon and vagina were purchased from Biochain 
(Newark, CA). From each RNA sample, 2 μg was used to synthesize cDNA using a 
Maxima First-Strand cDNA Synthesis Kit (Thermo Fisher Scientific) for use in qRT-
PCR. A standard curve was generated using glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) PCR products cloned into pJET1.2/blunt cloning vectors (Thermo Fisher 
Scientific). Primers used are presented in Table 1. qRT-PCR was run using Maxima 
SYBR Green qPCR Master Mix (Thermo Fisher Scientific), with the following thermal 
cycling conditions: 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s, 60 °C for 
30 s, and 72 °C for 30 s. GAPDH was used for normalization of mRNA levels. Statistical  
analysis was carried out using two-tailed unpaired t-tests, and p ≤ 0.05 was considered 
significant. Significance was denoted as follows: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 
0.001. 
Mucosal tissue samples 
Healthy subjects were recruited for tissue donation after providing written informed 
consent for participation in a protocol approved by the institutional review board of Johns 
Hopkins Medical Institutions. Each colorectal tissue donor provided 30 biopsies 
(approximately 25 mg each) and each vaginal donor provided 5 biopsies (approximately 
25 mg each). Donors are denoted by 1, 2, and 3; colon 3 and vagina 3 were obtained from 
the same individual. These same subjects were used in a previously published study [22]. 
Upon collection, biopsies were placed into RPMI 1640 medium (Corning Inc, Corning, 
NY) supplemented with 10% heat inactivated fetal bovine serum, penicillin-




Primer Accession Number Role Primers (5'3') Coordinates 
GAPDH NM_002046.3 Forward CTTCTTTTGCGTCGCCAGCCGA 62-83 
Reverse CACGACGTACTCAGCGCCAGC 390-370 
NDPKA NM_198175.1 Forward AAACCTAAGCAGCTGGAAGGG 85-105 
Reverse AGTTGGCCATGGTTCCTGTAT 318-338 
AK2 NM_001625.3 Forward GATGCTGGGAAACTGGTGAGT 288-308 
Reverse GCCTGTCCTATCATTCCCACC 869-849 
AK7 NM_152327.3 Forward TTGGATTCCTACAGCAGCGG 117-136 
Reverse TCAGAATCCTCGGGGTCCAG 553-534 
GUK1 NM_001242840.1 Forward GCCGACATGGAGAGCAGAAAT 598-618 
Reverse CCCTGGGTCCAGAGTGAGAG 860-841 
CKB NM_001823.4 Forward GGCCTCACCCAGATTGAAACTC 872-893 
Reverse ACTGCCCAGGCAATAAGTTAGG 1309-1288 
CKM NM_001824.4 Forward TTGACGTGTCCAACGCTGATC 1176-1196 
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  Reverse TCAATGGACTGGCCTTTCTCC 1296-1276 
CKMT1 NM_001015001.1 Forward GGCCTCAAAGAGGTGGAGAG 1257-1276 
Reverse GCTGGCGATGGGGAGTTAAT 1661-1642 
CKMT2 NM_001825.2 Forward CACACTAAACGGGTTGGGGA 90-109 
Reverse GTCTGGGTAGTCTGCGCTTG 410-391 
PKM NM_002654.4 Forward CAGAGGCTGCCATCTACCAC 1438-1457 
  Reverse CCAGACTTGGTGAGGACGAT 1588-1569 
PKLR NM_181871.3 Forward CTGGTGATTGTGGTGACAGG 1690-1709 
  Reverse TGGGCTGGAGAACGTAGACT 1839-1820 
OAT1 NM_001145946.1 Forward TGTGGCCTTAAACTTGCAGC 86-105 
  Reverse CAAGGCACACAAGAACACCTTT 502-481 
OAT3 NM_004254.3 Forward CTTCCTATCATCCTGGTGGAC 889-909 
  Reverse TAGAGGAAGAGGCAGCTGAAG 1417-1437 
MDR1 NM_000927.4 Forward CATTCAGTCAATCCGGGCCGGG 234-255 
  Reverse TCCATTCCGACCTCGCGCTCCTT 498-476 
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MRP1 NM_004996.3 Forward AACCTCAGTGTCGGGCAGCG 4460-4479 
  Reverse CTGGGGCTCACACCAAGCCG 4778-4759 
MRP3 NM_003786.3 Forward TTCCTCTGGCAGAACCTAGGTCCCT 1407-1431 
  Reverse GACACAAAGGCCTTCTCGGCGTC 1792-1770 
MRP4 NM_005845.3 Forward TCTCTGTGGCTGTGGCCGTGAT 2680-2701 
  Reverse AACCTGCCCGGCATCCAGAGTTTT 3056-3033 
MRP5 NM_005688.2 Forward TCGTGCGGTCTTGGTCGCTTG 854-874 
  Reverse AGCCGTGATGCAAACATCATTGCTG 1181-1157 
MRP8 NM_032583.3 Forward GCTGAAAGAATTGGCAGGAACT 39-60 
  Reverse ATGCCCAGAAGTGCATCGAA 557-576 
ENT1 NM_001078174.1 Forward ACTCCAAAGTCTCAGCAGCAGGCC 261-284 
  Reverse AGAGTTCCGCTCAGGCAAGGGT 557-536 
ENT2 NM_001532.2 Forward CGCATTCTGGGCAGCCTGCT 521-540 
  Reverse CACGCCACTGGCCATGGACA 787-768 
BCRP NM_004827.2 Forward TGGCTGTCATGGCTTCAGTA 2183-2202 
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  Reverse GCCACGTGATTCTTCCACAA 2388-2369 
OCT1 NM_003057.2 Forward ACGGTGGCGATCATGTACC 808-826 
  Reverse CCCATTCTTTTGAGCGATGTGG 1035-1014 
OCT2 NM_003058.3 Forward AGACAGTGTAGGCGCTACGA 433-452 
  Reverse GTTAAACTCGGTGACGATGGAC 594-573 
 
Table 1. Primers used in qRT-PCR for nucleotide kinases and transporters. 
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twice in 500 µL PBS and homogenized on ice in cell lysis buffer (Cell Signaling 
Technology, Danvers, MA) containing Halt Protease + Phosphatase Inhibitor Cocktail 
(Thermo Fisher Scientific) and 1 mM phenylmethanesulfonylfluoride (Sigma-Aldrich) 
using disposable pellet mixer pestles attached to a pestle motor (VWR International, 
Radnor, PA). 
Separation of CD4+ and CD4- populations from total PBMCs and lysis 
LeukoMAXTM Source Leukopaks were obtained from Bioreclamation (Westbury, NY) 
and subjected to several rounds of red blood cell lysis. To prepare the red blood cell lysis 
buffer, NH4Cl (0.35 g) and NaHCO3 (0.0036 g) were dissolved in 50 mL Molecular 
Biology Grade Water and the solution filtered through 0.22 μm Steriflip-GV filter units 
(Millipore, Billerica, MA). Cells were suspended in the lysis solution, incubated at room 
temperature for 10 min, then collected via centrifugation for 5 min at 400 g, 4 °C. If the 
resulting pellet was not white, the cells were resuspended in a fresh batch of lysis solution 
and the incubation and collection repeated. After the final collection, cells were washed 
twice with PBS and resuspended in cold MACSTM buffer (PBS with 0.5% BSA and 2 
mM EDTA). The CD4+ and CD4- populations were then separated using human anti-
CD4 microbeads (Miltenyi Biotec, Auburn, CA) on a LS Column (Miltenyi Biotec) 
attached to a MidiMACSTM Separator (Miltenyi Biotec) following the manufacturer’s 
instructions. Cells were washed twice with PBS and lysed on ice in cell lysis buffer (Cell 
Signaling Technology, Danvers, MA) containing Halt Protease + Phosphatase Inhibitor 
Cocktail (Thermo Fisher Scientific) and 1 mM phenylmethanesulfonylfluoride (Sigma-
Aldrich). Samples were centrifuged for 10 min at 3000 g, 4 °C and the resulting 
supernatant was stored at -20 °C. 
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Primary human hepatocyte culture and lysis 
Primary human hepatocytes with Matrigel overlay were obtained from Xenotech, LLC 
(Lenexa, Kansas). Donor was a 42 year old male, lot number 1168, and viability was 
82.7%. Upon receipt of the hepatocytes, shipping medium was replaced with William’s E 
medium (Life Technologies) containing 10% fetal bovine serum (Life Technologies), 
penicillin-streptomycin (Sigma-Aldrich), and L-Glutamine (Life Technologies). 
Hepatocytes were incubated overnight at 37 °C in a 5% CO2 humidified environment 
then collected with a cell scraper (Corning Inc.), washed twice with PBS, and lysed as 
described above. 
HepG2 cell culture 
HepG2 cells were obtained from the American Type Culture Collection. Upon receipt, 
the cells were thawed at 37 °C and seeded into Minimum Essential Medium with L-
Glutamine (Quality Biological) containing 10% fetal bovine serum (Life Technologies), 
penicillin-streptomycin (Sigma-Aldrich), and 1 mM sodium pyruvate (Sigma-Aldrich). 
Cells were grown at 37 °C in a 5% CO2 humidified environment.  
Immunoblotting 
Human total PBMC protein lysate was purchased from Biochain and human liver tissue 
lysates were obtained from Abcam (Cambridge, MA). Protein concentrations were 
determined using a Pierce® BCA Protein Assay Kit (Thermo Scientific), following the 
manufacturer’s instructions. For immunoblots, 10 µg of each sample were loaded onto 
10% or 12% Mini-PROTEAN® TGX™ Precast Gels (Bio-Rad, Hercules, CA) for 
separation via SDS-polyacrylamide gel electrophoresis. Proteins were transferred onto 
0.2 µm pore nitrocellulose membranes (Life Technologies) and blotted with 
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commercially available antibodies. Antibodies for BCRP, ENT1, NDPKA, AK2, GUK1, 
CKB, CKM, CKMT1, CKMT2, PKLR, and PKM were obtained from Thermo Fisher 
Scientific and antibody for AK7 was obtained from Sigma-Aldrich. Anti-β-actin was 
used for normalization and was obtained from Cell Signaling. Proteins were visualized 
using SuperSignal West Dura Chemiluminescent Substrate (Thermo Fisher Scientific) 
according to the manufacturer’s protocol and imaged with a Carestream 4000R system. 
Blots were stripped with ReBlot Plus Strong Antibody Stripping Solution (Millipore), 
then blotted with different antibodies following confirmation of antibody stripping. 
Targeting of nucleotide kinases using siRNA 
Nucleotide kinases were knocked down in PBMC, vaginal tissue and colorectal tissue 
using siGENOME siRNA (Dharmacon, GE Healthcare Life Sciences) delivered via 
electroporation. PBMC and vaginal tissue were transfected with siRNA targeted to AK2, 
GUK, PKM and PKLR while siRNA targeted to AK2, GUK and CKM were delivered to 
colorectal tissue. PBMCs and tissues transfected with non-targeting siGENOME siRNA 
were used as controls. For transfection of PBMC a Neon™ Transfection System (Life 
Technologies) was used and the cells were prepared for transfection according to 
manufacturer instructions for the 100 μL tip transfection kit. Electroporation conditions 
for PBMC were as follows: pulse voltage 2100 v, pulse width 15 ms, 1 pulse, 1 x 106 
cells and 500 nM siRNA. For tissue electroporation, vaginal and colorectal tissues were 
washed twice with serum-free DMEM followed by washing with OptiMEM (Life 
Technologies) a total of 5 mg of tissue was used for a single electroporation. The tissues 
were then electroporated in 0.4 cm cuvettes (Bio-Rad, Hercules, CA) using a Gene Pulser 
Xcell™ electroporater (Bio-Rad). A square waveform (500 V and 10 ms) and 500 nM of 
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siRNA was used. Following electroporation, tissues were cultured for 24 hr in DMEM 
supplemented with 10% FBS prior to homogenization for immunoblotting. To examine 
the impact of nucleotide kinase knockdowns on phosphorylation of TFV, TFV (10 μM) 
was added to the culture medium 24 hr (for vaginal and colorectal tissues) or 48 hr (for 
PBMC) after electroporation. Following 12 hr of incubation with TFV, the tissues and 
cells were harvested and homogenized in 70% methanol. The samples were then 
centrifuged for 10 min at 1,500 x g at 4ºC and the supernatant was dried under vacuum in 
preparation for analysis using ultra high performance liquid chromatography tandem 
mass spectrometry (uHPLC-MS/MS). 
Ultra high performance liquid chromatography mass spectrometry (uHPLC-MS) 
A uHPLC-MS assay was developed for the quantification of TFV, TFV-MP, and TFV-
DP using a Dionex Ultimate 3000 uHPLC system coupled to a TSQ Vantage Triple Stage 
Quadrupole mass spectrometer (Thermo Fisher Scientific). For the weak anion exchange 
assay, compounds were separated using a BioBasic AX column (5 μm, 50 mm x 2.1 mm, 
Thermo Fisher Scientific) at a flow rate of 0.25 mL/min. Solvent A was 10 mM 
ammonium acetate in 30% acetonitrile in water, pH 6.0 and solvent B was 1 mM 
ammonium acetate in 30% acetonitrile in water, pH 10.5. The pH of solvents was 
adjusted using acetic acid and ammonium hydroxide. The gradient used is as follows: 
10% B from 0.0 to 0.5 min, 50% B from 0.51 to 1.75 min, 100% B from 1.76 to 4.5 min, 
10% B from 4.6 to 6.6 min. For the ion pairing assay, compounds were separated using a 
Hypersil GOLD-C18 column (3 µm, 100 mm x 1 mm, Thermo Fisher Scientific) at a 
flow rate of 0.05 mL/min. Solvent A was 2 mM ammonium phosphate (Thermo Fisher 
Scientific) and 3 mM hexylamine (Thermo Fisher Scientific) in water, pH 9.2, and 
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solvent B was acetonitrile. The pH of solvent A was adjusted using ammonium 
hydroxide. The gradient used is as follows: 9% B from 0-0.5 min, 9% B to 60% B from 
0.5 to 15.5 min, 60% B to 9% B from 15.5-15.6 min, and held at 9% B until 29.6 min. In 
selected reaction monitoring mode, fragment ions were detected in positive ion mode 
using the following transitions (Q1Q3): TFV (m/z 288  176); TFV-MP (m/z 3668  
270); and TFV-DP (m/z 448  270). The sample tray was kept at 4 °C and solvents were 
refreshed weekly. Dried cell and tissue extracts were reconstituted in 100 µL mobile 
phase A for injection.  
Statistical Analyses 
All data presented are means ± S. E. from three independent experiments. Two-tailed 
unpaired t tests were performed to compare datasets, and p ≤ 0.05 was considered 




Nucleotide Kinase and Transporter mRNA Expression in PBMCs, Colorectal 
Tissues, and Vaginal Tissues 
It is yet unknown which nucleotide kinases are expressed in the tissues of relevance. We 
probed for mRNA expression of nucleotide kinases that may play a role in the activation 
of TFV in PBMCs, colorectal tissue, and vaginal tissue via qRT-PCR (Fig 1). The 
colorectal tissues showed higher mRNA levels of CKB as compared to both PBMCs (p-
value = 0.014) and vaginal tissues (p-value = 0.006). On the contrary, vaginal tissue 




















































Figure 1. Expression of nucleotide kinase mRNA in PBMCs, colorectal tissues, and 
vaginal tissues. Quantification of mRNA expression levels of candidate nucleotide 
kinases using qRT-PCR in PBMCs, colorectal tissue, and vaginal tissue (n=3). Statistical 
analyses were performed via two-tailed unpaired student’s t-tests to compare expression 































































Figure 2. Expression of transporter mRNA in PBMCs, colorectal tissues, and 
vaginal tissues. Quantification of mRNA expression levels of transporters using qRT-
PCR in PBMCs, colorectal tissue, and vaginal tissue (n=3). Statistical analyses were 
performed via two-tailed unpaired student’s t-tests to compare expression between all 









Colorectal tissues also showed lower mRNA levels of PKM as compared to PBMCs (p-
value = 0.038) and vaginal tissues (p-value = 0.002). 
 The expression of drug transport enzymes in these tissues has also not been 
thoroughly examined. We investigated mRNA expression of transporters that may 
participate in the influx or efflux of TFV in PBMCs, colorectal tissue, and vaginal tissue 
via qRT-PCR (Fig 2). Expression for OAT3 was not detected despite using primers  
validated in a previously published study [23]. Colorectal tissues exhibited higher mRNA 
levels of MRP3, MRP8, and OCT1 versus PBMCs (p-value = 0.032, 0.035, and 0.028 
respectively) and vaginal tissues (p-value = 0.031, 0.034, and 0.012 respectively). The 
mRNA level of ENT2 was also higher in colorectal tissues than vaginal tissues (p-value = 
0.044). Vaginal tissues displayed higher mRNA levels of MDR1 versus both PBMCs (p- 
value = 0.041) and colorectal tissues (p-value = 0.042) and higher mRNA levels of 
MRP5 and ENT1 versus PBMCs (p-value = 0.011 and 0.005, respectively).  
Nucleotide Kinase and Transport Protein Expression in PBMCs, Colorectal Tissues, 
and Vaginal Tissues 
Nucleotide kinase expression was also examined on the protein level via immunoblotting 
using cell lysates (Fig 3). Protein expression of NDPKA was not detected in any samples 
despite evidence of mRNA expression. Of the adenylate kinases, expression of AK2 was 
detected in all three tissues with greater expression in colorectal tissue than vaginal, and 
AK7 was detected only in colorectal tissue. The AK7 antibody also detected a band at 
approximately 90 kDa in vaginal tissue that did not match the molecular weight of AK7 
(83 kDa). Meanwhile, protein expression of PKLR and PKM was detected in all three 




Figure 3. Protein expression of nucleotide kinases and transporters in PBMCs, 
colorectal tissues, and vaginal tissues. Immunoblots of nucleotide kinases in protein 
lysates isolated from PBMCs and colorectal and vaginal biopsies. After imaging, blots 


















































































Figure 4. Immunoblots of nucleotide kinases in protein lysates isolated from 
colorectal tissue and vaginal tissue biopsies from multiple donors. Colon 3 and vagina 
3 are from a single individual. 
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was detected most strongly in vaginal tissue, less strongly in colorectal tissue, and was 
undetected in PBMCs. The source of the multiple bands detected by the anti-GUK1 
antibody is unknown as their migration does not match the expected migration from 
known splice variants of GUK1 [24]. Lastly, CKB, CKM, CKMT1, and CKMT2 all 
showed significantly higher protein expression in colorectal tissue over PBMCs and 
vaginal tissue. The greater expression of AK2, CKB, CKM, CKMT1, and CKMT2 in 
colorectal versus vaginal tissue was further confirmed through immunoblots using cell 
lysates from three individual colorectal and vaginal tissue donors (Fig 4). The markedly 
higher expression in colorectal versus vaginal tissue is consistent across multiple donors 
including the third colon and third vagina sample that are from the same individual.  
 The expression of transport proteins shown or proposed to demonstrate activity 
towards TFV was also examined in these tissues (Fig 3). Expression of equilibrative 
nucleoside transporter 1 and breast cancer resistance protein was observed in colorectal 
and vaginal tissues, with no expression detected in PBMCs. Other transporters that could 
not be detected in any of the three tissues were multiple drug resistance-associated 
proteins 1, 4, and 5, and organic anion transport protein 1. 
Differences in Nucleotide Kinase Protein Expression between Circulating CD4+ and 
CD4- Cells 
While PBMCs are often used to study HIV drug anabolism, it is only the CD4+ T cells 
that are susceptible to infection. However, potential differences in nucleotide kinase 
expression between the CD4+ T cells and the CD4- expressing cells that are present in 
PBMC isolations are unknown. In order to explore these expression patterns, PBMCs 
were obtained from three individual donors, the CD4+ population and CD4- populations 
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were separated and lysed, and nucleotide kinase expression examined via 
immunoblotting (Fig 5). Because only AK2, GUK1, PKLR, and PKM were previously 
detected in PBMCs (Fig 3), only these nucleotide kinases were examined here. All 
kinases were detected in both cell populations, but no consistent differences in expression 
levels were evident. However, two bands are detected in CD4+ cells when 
immunoblotting for GUK1, whereas only one is detected in the CD4- population (Fig 5). 
The migration and separation of the two GUK1 bands seen in CD4+ cells match those 
observed in the previously screened colon tissue.   
Expression of Nucleotide Kinase Protein in Liver Tissues, Hep-G2 Cells, and 
Primary Human Hepatocytes 
Next, we examined the expression of kinases that may activate TFV in the liver via 
immunoblotting of liver tissue lysates (Fig 6A). Protein expression of AK2, GUK1, 
PKLR, PKM, and CKM is detected in all 3 human liver lysates. Expression was also  
compared between primary human hepatocytes and the HepG2 hepatocellular carcinoma 
cell line in order to assess the feasibility of using HepG2 as a model in subsequent studies 
(Fig 6B). AK2, GUK1, PKLR, and PKM are highly expressed in HepG2 cells. The CKM 
antibody detects two proteins in HepG2 cells that migrate faster and slower than the 
CKM protein detected in human hepatocytes. 
A uHPLC-MS Assay to Simultaneously Detect TFV, TFV-MP, and TFV-DP 
Further studies to determine which nucleotide kinases exhibit activity towards TFV 
intracellularly require an assay that quantitates TFV, TFV-MP, and TFV-DP, thus an 
uHPLC-MS assay was developed using weak anion exchange. While the chromatography 




Figure 5. Protein expression of nucleotide kinases in CD4+ cells and CD4- cells in 
total PBMC population. PBMCs were obtained from healthy donors and the CD4+ and 
CD4- cell populations were isolated via magnetic separation. Protein lysates were then 
obtained and immunoblotted to probe for nucleotide kinase expression. Individual donors 








Figure 6. Protein expression of nucleotide kinases in human liver tissue, primary 
human hepatocytes, and HepG2 cells. A. Immunoblots of nucleotide kinases in human 
liver tissue lysates. Individual donors are indicated by L1, L2, and L3. B. Immunoblots 























1    2    3 
Liver 
1    2    3 
Liver 


























































and mass spectrometer settings are novel. Samples of each analyte were commercially 
obtained and detected using the following mass transitions: TFV (m/z = 288  176), 
TFV-MP (m/z = 368  270), and TFV-DP (m/z = 488270) (Fig. 7). It was noted that 
when injecting pure TFV-MP, ions were detected in the chromatogram of TFV at the 
retention time of TFV-MP, and similarly when injecting TFV-DP, ions were detected in 
the chromatograms of TFV and TFV-MP at the retention time of TFV-DP. Because this 
in source fragmentation presents a barrier to quantitation, various aspects of the mass 
spectrometer settings were further optimized subsequent to instrument tuning. Decreasing 
neither the spray voltage nor the vaporizer temperature had a significant effect, but 
decreasing the capillary temperature to 150 °C resulted in minimal in source 
fragmentation. TFV-MP was detected as low as 100 fmol while TFV and TFV-DP were 
detected as low as 10 fmol.  TFV-MP and TFV-DP only displayed in source 
fragmentation at 1 pmol.  
 Unfortunately, the weak anion exchange chromatography displayed poor day to 
day reproducibility in terms of peak shape, retention times, and compound separation. 
The uHPLC-MS assay was redeveloped with ion pairing chromatography, using the 
column, solvents, and elution gradient of a previously published assay [26]. The mass 
spectrometry conditions with the decreased capillary temperature of 150 °C were used 
with the published chromatography column, buffers, and elution gradient.  
Activation of TFV in PBMCs, Colorectal Tissues, and Vaginal Tissues 
Leveraging the above expression data, we predicted that in PBMCs, colorectal tissues, 
and vaginal tissues, AK2 and GUK1 could be responsible for the first phosphorylation 




Figure 7. Lower limits of detection for TFV, TFV-MP, TFV-DP in the weak anion 
exchange uHPLC-MS assay. Injections of TFV (10 fmol), TFV-MP (100 fmol), and 
TFV-DP (10 fmol) are displayed from left to right. The following transitions are used 







second phosphorylation step, and in colorectal tissues any of the CKs could perform this 
step. We sought to confirm this by using targeted siRNA to knock down the protein 
expression of the predicted kinases in each cell or tissue type. Detection of kinase 
expression via immunoblot showed that expression of all targeted kinases was decreased 
when compared to the non-targeting siRNA control (Fig 8A). Following incubation 
of the siRNA treated cells and tissues with TFV, the intracellular metabolites were 
extracted and detected using the ion pairing uHPLC-MS/MS assay (Fig 8B).  When AK2 
was knocked down, production of TFV-MP decreased to 17 ± 1.4%, 9.5 ± 1.1%, and 12 ± 
1.5% (p-value = 3.4E-6, 3.6E-5, and 7.2E-5) of the non-targeting siRNA control in 
PBMCs, colorectal tissues, and vaginal tissues,  
respectively. The decrease in AK2 expression also resulted in decrease of TFV-DP 
production to 13 ± 1.7%, 15 ± 2.3%, and 9 ± 2.2% (p-value = 3.9E-6, 4.5E-6, and 2.7E-5) 
of the non-targeting siRNA control in PBMCs, colorectal tissues, and vaginal tissues, 
respectively. Knockdown of PKM decreased TFV-DP production to 33 ± 5.8% and 27 ± 
4.3% (p-value = 2.7E-5 and 8.2E-5) and knockdown of PKLR decreased TFV-DP 
production to 78 ± 6.6% and 81 ± 7.4% (p-value = 0.008 and 0.017) of the non-targeting 
control in PBMCs and vaginal tissues, respectively. When CKM was knocked down in 
colorectal tissues, production of TFV-DP was decreased to 8 ± 2.9% (p-value = 2.2E-5) 
of the non-targeting control. 
 
Discussion 
This study shows for the first time which nucleotide kinases are able to perform the 




Figure 8. Knockdown of nucleotide kinases in PBMCs, colorectal tissues, and 
vaginal tissues, and effects on TFV metabolism. A. PBMCs, colorectal tissues, and 
vaginal tissues were electroporated with non-targeting siRNA or siRNA targeting 
nucleotide kinases. Representative immunoblots showing the extent of protein expression 
decrease are shown. B. SiRNA treated PBMCs, colorectal tissues, and vaginal tissues (n 
= 3) were incubated with 10 µM TFV for 12 hours. Intracellular metabolites were 
extracted and TFV-MP and TFV-DP were detected using the ion pairing uHPLC-MS/MS 
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assay. Statistical analyses were performed via two-tailed unpaired student’s t-tests to 
compare metabolite production between non-targeted and targeted siRNA conditions; * = 

















tissues. It also examines the expression patterns of candidate nucleotide kinases in tissue 
of interest, enabling a detailed understanding of how TFV can be activated in PBMCs, 
circulating CD4+ cells, colon tissue, vagina tissue, and liver tissue. The expression 
differences observed between various tissue types may have implications on the efficacy 
of HIV treatment and prevention, but the small number of samples employed is a 
potential limitation. Nevertheless, these data lay the groundwork for future studies to gain 
a comprehensive understanding of NRTI activation in these tissues and leverage this 
knowledge to optimize the use of antiretroviral drugs.  
 Previous studies showing that CKs and PKs exhibit activity towards TFV-MP 
were carried out in vitro and the study identifying AK2 as the enzyme responsible for 
phosphorylating TFV reached its conclusions through elimination of AK1 and AK3. 
Lastly, GUK1 has never been examined for activity towards TFV. Here we leverage 
targeted siRNAs to specifically knockdown AK2 and GUK1 in PBMCs, colorectal 
tissues, and vaginal tissues, PKM and PKLR in PBMCs and vaginal tissues, and CKM in 
colorectal tissues. Subsequent incubations with TFV revealed that AK2 is responsible for 
the first phosphorylation step of TFV in PBMCs, vaginal tissues, and colorectal tissues. 
The second phosphorylation step is carried out primarily by PKM and by PKLR to a 
lesser extent in PBMCs and vaginal tissues. In colorectal tissues, CKM is responsible for 
the majority of the second phosphorylation step. Although the potential contribution of 
CKB, CKMT1, CKMT2, PKM, and PKLR was not examined in colorectal tissues, it is 
clear that their combined contributions to the second phosphorylation step are less than 
that of CKM. 
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 It was observed that AK2, CKB, CKM, CKMT1, and CKMT2 are expressed at 
higher levels in colorectal tissue than in PBMCs and vaginal tissue. In the PBMCs and 
vaginal tissues which have little to no creatine kinase expression, the second 
phosphorylation step of TFV may be carried out by pyruvate kinases. Additionally, the 
muscle and brain isoforms of creatine kinase were previously shown to catalyze the 
phosphorylation of TFV-MP with greater efficiency than pyruvate kinase [10]. Thus, the 
observation that TFV-DP is found in much greater quantities in colorectal tissues over 
vaginal tissues after a single oral dose [21, 27] could be explained by the higher 
expression levels of enzymes capable of phosphorylating TFV in the colon mucosa, the 
greater efficiency of creatine kinases, or both. Further possibilities include differential 
distribution of TFV to the colon and vagina, or different absorption rates. However, when 
an individual is exposed to HIV through the mucosal tissues, the virus will specifically 
target the CD4+ cells within the tissues [28]. These tissue specific CD4+ cells should have 
the same TFV activation pathway as systemic CD4+ cells, so it is not clear how increased 
TFV-DP levels in the surrounding colon tissue provide a higher barrier to HIV infection. 
Nevertheless, clinical trials support the existence of a colon advantage for prevention of 
HIV infection using TFV. Adherence to the drug regimen was found to be low in trials 
testing transmission of HIV infection in both the homosexual male population (iPrEx), 
who are vulnerable to infection via the colon, and to the heterosexual female population 
(FEM-PrEP, VOICE), who are primarily vulnerable to infection via the vagina [29-31]. 
Yet, the iPrEx trial showed a 44% reduction in HIV infectivity whereas FEM-PrEP and 
VOICE could not demonstrate similar protection. Further work may help to elucidate the 
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mechanism behind this colon advantage and determine whether the differential activation 
of TFV between the colon and vagina plays a significant role.  
 The most striking difference between CD4+ cells and CD4- cells in the total 
PBMC population was the presence of two bands in CD4+ cells when probing for GUK1. 
The ability of GUK1 to phosphorylate TFV has not been examined, though the detection 
of GUK1 expression in PBMCs and CD4+ cells shows that GUK1 may be one of the 
factors that determine intracellular concentrations of amdoxovir in these cells. Otherwise, 
there are few differences between expression levels of AK2, PKLR, and PKM in CD4+ 
cells and CD4- cells.  
 Understanding which enzymes are responsible for the activation of these drugs in 
which tissues sets the groundwork for a pharmacogenomically-sensitive approach to 
understanding HIV and HBV treatment. Single nucleotide polymorphisms and other 
mutations that cause decreased enzyme function or expression have been identified for 
AK2 [32], PKLR [33], and CKB [34]  and correlated to human disorders. Patients with 
one of these mutations may not efficiently activate NRTIs in the targeted cell types, and 
thus treatment with these drugs would not only be unsuccessful, but may also facilitate 
the spread of drug resistant virions or result in other undesirable side effects.  There is 
clear precedent for using genetic information for selection (or avoidance) of certain drugs 
for which an individual patient has an increased sensitivity on a genetic basis. For 
example, it is standard practice to genotype patients for HLA-B*5701 before prescribing 
an abacavir containing regimen, and there is ongoing work studying the association of 
TFV induced renal toxicity with SNPs in drug transport proteins [35].  
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 In contrast to the data presented here showing that the efflux proteins MRP1, 
MRP3, and MRP4 could not be detected in PBMCs, a previous study showed using the 
known substrate carobxy-2’,7’-dichlorofluorescein that MRP is active in these cells [36, 
37]. MDR1 activity was also demonstrated in PBMCs via a rhodamine 123 efflux assay, 
corroborating the findings of MDR1 mRNA expression in PBMCs in this study and 
mRNA expression and activity in a separate study [37]. Expression of BCRP on the 
mRNA level was also shown in PBMCs, which is in line with the present findings 
although we did not detect BCRP on the protein level [37]. To our knowledge, no work 
has been done examining the expression of OAT1, OAT3, ENT1, OCT1, and OCT2 in 
PBMCs on the mRNA or protein level, nor on BCRP at the protein level. Colorectal 
tissues have been shown to express MDR1, MRP1/3/4/5, BCRP, and OCT1 on the 
mRNA level, with no evidence of OCT2, OAT1, and OAT3 [38]. Protein expression of 
MRP4 and OAT1 has also been detected [39].  The current study was able to detect 
MRP4 and OAT1 mRNA in colorectal tissues; however, protein expression was not seen. 
Vaginal tissues have been shown to express MDR1, MRP1, MRP4, MRP7, BCRP, 
OAT1, and OAT3 on the mRNA level and MDR1 and MRP4 expression on the protein 
level [39, 40]. The mRNA expression data is corroborated in the present study whereas 
the protein expression data are not. Observed discrepancies in transporter expression 
between the present data and previously published studies are likely due to inter-
individual variability; the present study is hampered by the limited number of donors. 
Nevertheless, while PBMCs, colorectal tissues, and vaginal tissues express various 
transporters capable of TFV efflux, potential TFV influx pathways are yet unclear. The 
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only transporters known to be capable TFV uptake, OAT1 and OAT3, have so far not 
been detected on the protein level in these cell/tissue types. 
 In summary, the present study demonstrates that AK2, PKM, and PKLR are 
responsible for activating TFV in PBMCs and vaginal tissues whereas AK2 and CKM are 
responsible for activating TFV in colorectal tissues. It also examines the protein 
expression of nucleotide kinases proposed to activate TFV in vitro in PBMCs, circulating 
CD4+ cells, colon tissue, vagina tissue, and liver tissue and investigates expression of 
transporters predicted to mediate the influx or efflux of TFV. Protein activity and 
expression results from this study and previously published studies are summarized in 
Figure 9. We anticipate that these data can be leveraged in future studies to facilitate a 
rational in depth approach to optimal use of these drugs for treatment and prevention of 





Figure 9. Proposed metabolism scheme of TFV in PBMCs, colorectal tissue, and 
vaginal tissue. Scheme is based off of protein expression and activity studies performed 
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Chapter 4: Final Conclusions 
Drugs that are not given orally may never encounter the liver, which is the primary organ 
associated with drug metabolism. Antiretroviral drugs such as dapivirine and tenofovir 
are being developed for topical use in the colorectal and vaginal areas to prevent the 
establishment of HIV infection.  As such, the metabolism of these drugs must be 
understood in these tissues to ensure optimal drug use. The studies presented here 
investigate the ability of the colorectal and vaginal tissue to metabolize these 
antiretrovirals, thus informing not only HIV PrEP, but also all further drugs that will be 
administered in these tissues. 
 Previous studies of P450 expression in the vaginal and colorectal areas were not 
comprehensive and sometimes looked only at mRNA levels without checking protein 
levels. Additionally, evidence of P450 activity has never been shown. In Chapter 1, the 
P450 and UGT mediated metabolism of dapivirine was determined by use of in vitro 
enzyme assays and uHPLC-MS. Armed with this knowledge, dapivirine was then used as 
a small molecule probe to investigate enzymatic activity in colorectal and vaginal tissues 
obtained from healthy human donors. Colorectal tissues were shown to produce both 
P450 and UGT mediated metabolites of dapivirine, whereas vaginal tissues only 
produced P450 mediated metabolites. This is the first direct evidence for such enzymatic 
activity in these tissues, and the first evidence that metabolism differs in the two areas. 
The lack of UGT activity also differentiates vaginal tissue metabolism from hepatic 
metabolism. Due to the difficulty of isolating microsomes from the limited colorectal 
tissue available from healthy donors, however, a direct comparison of relative 
metabolism activity between colorectal tissues and hepatocytes could not be performed. 
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The fact that not all of the P450 nor UGT mediated metabolites produced by human liver 
microsomes were produced by the colorectal biopsies may indicate lower metabolizing 
activity in the colorectal tissues, but there is nothing to normalize between the two 
systems.  
 The work in Chapter 2 also touched upon possible dapivirine mediated changes in 
the transcriptional regulation of CYP3A4. Because P450 induction or inhibition is the 
mechanism behind many drug-drug interactions, it is important to investigate potential 
drug dependent changes in P450 activity. Two other diarylpyrimidine drugs, etravirine 
and rilpivirine, were shown to induce CYP3A4 mRNA levels in a pregnane-X-receptor 
dependent manner [1, 2].  However, while etravirine and rilpivirine consistently induce 
CYP3A4 mRNA, dapivirine only does so in two out of three colorectal donors and in one 
out of three hepatocyte donors. The colorectal induction was shown in one donor to be 
PXR mediated by use of sulforaphane, a known PXR inhibitor. It is also interesting that 
etravirine and rilpivirine are orally bioavailable while dapivirine is not. Possible causes 
for these trends may be worth exploring, especially to discern whether the PXR 
dependent CYP3A4 induction and oral bioavailability of etravirine and rilpivirine may be 
related. One possibility may be the presence of two cyano groups in both etravirine and 
rilpivirine, but only one in dapivirine. Nevertheless, this work combined with the work 
done on etravirine and rilpivirine serve to establish the CYP3A enzymes as consistent 
metabolizers of diarylpyrimidine drugs. 
 Chapter 3 investigates the metabolism of tenofovir, a drug that not only is known 
to be activated through its metabolism, but is also known to be unaffected by P450s. 
Because tenofovir is administered in oral formulation for HIV and HBV treatment and 
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HIV PrEP, its metabolism must be understood in white blood cells and hepatocytes in 
addition to the colorectal and vaginal tissues. The active metabolite of tenofovir is 
tenofovir diphosphate, which is produced via two intracellular phosphorylation events by 
nucleotide kinases. While many candidate kinases have been proposed and examined via 
in vitro enzyme assays, the metabolism pathway for tenofovir in the various tissues is not 
well-defined. Expression profiling of candidate nucleotide kinases reveals that adenylate 
kinases and creatine kinases are expressed at much higher levels in colorectal tissues 
versus vaginal tissues and PBMCs whereas pyruvate kinases show the opposite trend. 
This is another example of differential drug metabolism in the colorectal and vaginal 
areas. Additionally, only expression of CKM, AK2, GUK1, PKM, and PKLR were 
detected in human liver tissues and primary human hepatocytes. This is further support 
for the difference in hepatic, colorectal, and vaginal drug metabolism. Interestingly, the 
nucleotide kinase expression in PBMCs seems to match that of vaginal tissues. The 
difference becomes evident upon examination of equilibrative nucleotide transporter 1 
and breast cancer resistance protein expression, which are detected in colorectal and 
vaginal tissues but not in PBMCs. 
 A previously published ion pairing uHPLC-MS/MS assay was used, after 
minimizing in source fragmentation, to determine which nucleotide kinases responsible 
for activating TFV in PBMCs, colorectal tissues, and vaginal tissues. Data from 
expression profiling informed the rational knockdown of AK2 and GUK1 in all three 
cell/tissue types, PKM and PKLR in PBMCs and vaginal tissues, and CKM in colorectal 
tissues. Subsequent to siRNA treatment, the cell/tissue samples were incubated with TFV 
and intracellular metabolites detected via uHPLC-MS/MS. It was concluded that AK2 
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carries out the first phosphorylation step of TFV in all three cell/tissue types. In PBMCs 
and vaginal tissues PKM carries out the second step with PKLR contributing to a lesser 
extent, and CKM performs the majority of the second step in colorectal tissues. The 
previously published in vitro evidence that CKs are much more active towards TFV than 
PKs, combined with the present in situ data, provide a mechanistic explanation for the 
observed phenomenon that TFV-DP is produced in greater quantities in colorectal versus 
vaginal tissues. 
 Collectively, these data represent a fundamental shift in the current understanding 
of drug metabolism. Not only do the colorectal and vaginal tissues metabolize drugs, but 
metabolism also differs between the two. Administration of drugs, including 
contraceptives and spermicides, to these tissues must first take P450 and UGT activity 
into consideration. The differential activation of tenofovir in colorectal versus vaginal 
tissues informs the future use of tenofovir and other NRTIs in these areas. Understanding 
which kinases activate tenofovir in which tissues also lays the groundwork for 
pharmacogenetic analyses to examine inter-individual differences in NRTI activation, 
which can be leveraged to optimize drug use for HIV treatment and prevention. 
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2009 
Project: Screening and isolation of single chain variable fragments (scFvs) to target 
proteins implicated in neurodegenerative disorders. 
 Identified and cloned two novel scFvs targeting DISC1 and two scFvs targeting 
amyloid beta peptide. 
 
Teaching Experience 




 Neuroscience course for Young Engineering and Science Scholars 
 Synthesis and Analysis of Organic and Inorganic Compounds (winter and spring 
quarters) 
 Experimental Procedures of Synthetic Chemistry 
 The Biology and Biophysics of Viruses 
 
Publications 
To, E. E., Hendrix, C. W., Bumpus, N. N. “Dissimilarities in the metabolism of 
antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues.” 
Biochem. Pharmacol. 2013; 86: 979-990. 
 
Honors and Awards 
 
Best Abstract Competition invitee (American Society for Pharmacology and 
Experimental Therapeutics, Drug Metabolism Division) at Experimental Biology, April 
2013. 
 
Rose Hills Foundation Summer Undergraduate Research Fellowship, California Institute 
of Technology, 2009. 
 






To, E. E. and Bumpus, N. N. “Mucosal Expression of the Cytochromes P450 (CYP) and 
Nucleotide Kinases Involved in the Biotransformation of Drugs used in Human 
Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis (PrEP).” Poster presentation at 
ASPET/British Pharmacological Society Annual Meeting at Experimental Biology, 
04/2013. 
 
To, E. E., Khoshnan. A, and Patterson, P. H. “Generation of Intrabodies as Molecular 
Tools to Dissect the Function of Disrupted in Schizophrenia 1 (DISC1).” Oral 
presentation at California Institute of Technology Summer Seminar Day, 08/2009. 
 
To, E. E., Khoshnan, A., and Patterson, P. H. “Isolation and Characterization of ScFvs 
that Bind to the Amyloid Beta Pyro Peptide.” Oral presentation at California Institute of 
Technology SURF Seminar Day, 10/2008. 
 
Professional Societies 
American Society for Pharmacology and Experimental Therapeutics (ASPET)  2012-
present 
 
Leadership, Management, & Outreach Experience 
Enrollment Coordinator & Divisional Leader, Incentive Mentoring Program, 
Baltimore, MD 
          2010-present 
128 
 
Streamlined enrollment procedures enabling over 700 new volunteers to commit to the 
organization and guided team leaders of 4 individual teams in accomplishing short and 
long term goals in tutoring and mentoring a high school student.   
 
Guest Blogger, Scizzle, Atlanta, GA      2013-present 
Contributed bimonthly blog posts summarizing scientific publications for a general 
audience. 
 
 
 
 
